# 1
## Summary
text
### <b><i style="color:red;">Infertility and Assisted Reproductive Technology (ART) Overview</i></b>

| Topic | Definition/Pathogenesis | Clinical Manifestations/Findings | Diagnosis/Work-up | Treatment/Management |
| :--- | :--- | :--- | :--- | :--- |
| <b style="color:red;">Infertility</b> | Inability to conceive after 1 year of unprotected sex (6 months if >35 years old). | Oligo/amenorrhea, known tubal obstruction, endometriosis. | Comprehensive history, PE, and ancillary testing (Semen analysis, HSG). | Ovulation induction, IUI, or IVF. |
| <b style="color:red;">Male Factor Infertility</b> | Issues with sperm production, motility, or morphology (25% of cases). | Low sperm count (oligospermia) or absence (azoospermia). | <b style="color:red;">Semen Analysis</b> (WHO 2010): Volume ≥1.5mL, Conc. ≥15M/mL, Motility ≥40%, Morph ≥4%. | Lifestyle changes, IUI, or IVF-ICSI. |
| <b style="color:red;">Ovulatory Disorders</b> | Dysfunction in the HPO axis leading to anovulation (27% of female factors). | Irregular cycles, low midluteal progesterone. | <b style="color:red;">Serum Progesterone</b> (>3 ng/mL = ovulation) and <b style="color:red;">BBT</b> (thermogenic shift). | <b style="color:red;">Clomiphene Citrate</b> or <b style="color:red;">Letrozole</b>. |
| <b style="color:red;">Tubal/Uterine Factors</b> | Physical blockages or structural abnormalities (22% tubal). | Hydrosalpinx, adhesions, submucous myomas. | <b style="color:red;">Hysterosalpingogram (HSG)</b> and Laparoscopy. | Tubal surgery, Myomectomy, or IVF. |
| <b style="color:red;">Endometriosis</b> | Inflammatory disease affecting 40% of infertile women. | Pain, reduced fecundity, mechanical obstruction. | Laparoscopy (Visual diagnosis). | COS + IUI; IVF if no pregnancy after 3-6 cycles. |
| <b style="color:red;">OHSS</b> | Iatrogenic complication of gonadotropin therapy. | Ovarian enlargement, ascites, hemoconcentration. | Monitoring E2 levels and follicle size; ultrasound for ascites. | Supportive care, fluids, electrolytes; avoid HCG trigger. |

---

### <b><i style="color:red;">Definitions & Epidemiology</i></b>

* <b style="color:red;">Infertility</b> is defined as the inability of a couple to achieve pregnancy within one year of unprotected frequent sexual contact.
* <b style="color:red;">Early Infertility evaluation (after 6 months)</b> is warranted for women >35 years old or those with oligo/amenorrhea, known tubal disease, severe endometriosis, or male factors.
* <b style="color:red;">Fecundability</b> is the monthly ability of a normal fertile couple to get pregnant, typically approximately 20%.
* <b style="color:red;">Female Infertility factors</b> account for 54% of cases, with <b style="color:red;">Ovulatory Disorders</b> (27%) and <b style="color:red;">Tubal Disorders</b> (22%) being the most common.
* <b style="color:red;">Unexplained Infertility</b> occurs in approximately 17-20% of couples where all standard diagnostic tests are normal.
* <b style="color:red;">Infertility prevalence</b> increases with the age of the female partner: 1 in 7 if age 30-34, 1 in 5 if age 35-40, and 1 in 4 if age 40-44.
* <b style="color:red;">Azoospermic husbands</b>: Even with donor insemination, the pregnancy rate in women decreases from 73% (age <25) to 55.8% (age 36-40).
* <b style="color:red;">Diminished Ovarian Reserve</b> is the most common diagnostic category among women undergoing IVF.

---

### <b><i style="color:red;">Physiology & Optimal Timing</i></b>

* <b style="color:red;">Oocyte lifespan</b>: An egg disintegrates less than 24 hours after reaching the ampulla.
* <b style="color:red;">Sperm lifespan</b>: Normal sperm retain fertilizing ability in the oviduct for up to 72 hours.
* <b style="color:red;">Optimal conception time</b>: Intercourse on the day before ovulation or daily for 3 days at mid-cycle yields the highest pregnancy rate (30%).
* <b style="color:red;">LH Surge detection (First morning urine)</b>: If positive, ovulation occurs on the same day of detection.
* <b style="color:red;">LH Surge detection (Random urine)</b>: Ovulation occurs 12 to 24 hours after a positive result (the suivant day).
* <b style="color:red;">Conception blockers</b>: Vaginal lubricants, saliva, cigarette smoking, and douching decrease the chance of conception.

---

### <b><i style="color:red;">Ovulation & Ovarian Reserve Assessment</i></b>

* <b style="color:red;">Serum Progesterone (Midluteal phase)</b>: Values >3-5 ng/mL suggest some ovulatory function; ≥10 ng/mL suggests a normal ovulatory cycle and potential conception.
* <b style="color:red;">Basal Body Temperature (BBT)</b>: Based on the thermogenic effect of progesterone on the hypothalamus; requires taking sublingual temperature shortly after awakening after 6 hours of sleep.
* <b style="color:red;">Endometrial Biopsy</b>: Formerly used to diagnose luteal phase defects, but is no longer indicated for routine infertility workup because it is invasive and subjective.
* <b style="color:red;">Ovarian Reserve Testing</b>: Primarily recommended for women >35, those with unexplained infertility, smokers, or those with a history of ovarian surgery/chemo/radiation.
* <b style="color:red;">Serum FSH (Day 2 or 3)</b>: Elevated levels (>10 mIU/mL) indicate decreased ovarian reserve; >20 mIU/mL indicates a poor prognosis.
* <b style="color:red;">Serum Estradiol (E2)</b>: Levels >70 pg/mL early in the cycle suggest poor prognosis or may invalidate FSH readings.
* <b style="color:red;">Anti-Müllerian Hormone (AMH)</b>: Produced by granulosa cells; <0.5 ng/mL indicates decreased ovarian reserve, while >2 ng/mL indicates more follicles are available.
* <b style="color:red;">AMH Menopause prediction</b>: An AMH level of 0.05 ng/mL suggests menopause will occur within 4-5 years.
* <b style="color:red;">Antral Follicle Count (AFC)</b>: Measured via TVS on cycle day 2 to 4; a count of 10 or more follicles (2-10 mm size) suggests good ovarian reserve.

---

### <b><i style="color:red;">Semen Analysis & Male Evaluation</i></b>

* <b style="color:red;">Male Infertility workup</b>: Includes 2-3 days of abstinence before semen collection; entire specimen should be collected in a wide-mouthed jar.
* <b style="color:red;">Sperm motility</b>: Begins to decline 2 hours after ejaculation; specimen must be examined within this period and kept warm.
* <b style="color:red;">Sperm morphology</b>: A subjective test reflecting sperm production from 3 months prior; only normal forms (Kruger criteria 4%) have fertilization ability.
* <b style="color:red;">Low normal sperm values (WHO 2010)</b>: Concentration 15 million/mL, total number 39 million/ejaculate, and 40% motility.
* <b style="color:red;">Intrauterine Insemination (IUI)</b>: Sperm must be washed and separated from seminal fluid; <b style="color:red;">Unwashed seminal fluid</b> must NOT be used because it contains prostaglandins that cause severe uterine cramps and infection.
* <b style="color:red;">IUI Limitations</b>: Less successful if significant <b style="color:red;">oligospermia</b> (<5 million motile sperm) is present.

---

### <b><i style="color:red;">Hysterosalpingography (HSG) & Tubal Disease</i></b>

* <b style="color:red;">HSG Timing</b>: Performed on the 10th day of the cycle (follicular phase) to avoid pregnancy and ensure better endometrial definition.
* <b style="color:red;">HSG Contraindications</b>: History of untreated salpingitis or tenderness on pelvic exam.
* <b style="color:red;">Water-soluble contrast</b>: Currently preferred over oil-soluble contrast to avoid peritoneal irritation and granulomas.
* <b style="color:red;">Doxycycline (100 mg BID)</b>: Prophylactic antibiotic given for 1-2 weeks if <b style="color:red;">hydrosalpinx</b> is visualized on HSG.
* <b style="color:red;">Hydrosalpinx (HSG)</b>: Appears as distal blockage with "ballooning" and a sausage-like appearance; spillage of dye is absent.
* <b style="color:red;">Proximal Tubal Obstruction</b>: May be due to true block (SIN, infection) or <b style="color:red;">cornual spasm</b> (false block).
* <b style="color:red;">Laparoscopic Salpingectomy</b>: Recommended prior to IVF for women with <b style="color:red;">large hydrosalpinx</b> because the fluid affects embryo implantation and decreases IVF success rates by 40%.
* <b style="color:red;">Tubal wall thickness</b>: The best prognostic factor for pregnancy after tubal reconstructive surgery.
* <b style="color:red;">Tubal Tuberculosis</b>: Radiographically appears as a "pipe stem" configuration; women with pelvic TB are considered sterile.

---

### <b><i style="color:red;">Medical Management of Anovulation</i></b>

* <b style="color:red;">Clomiphene Citrate (CC)</b>: A selective estrogen receptor antagonist; first-line for oligomenorrhea with sufficient estrogen. Dose is 50-150 mg for 5 days starting on day 3-5.
* <b style="color:red;">Clomiphene side effects</b>: 8% incidence of multiple gestations, ovarian cysts, vasomotor flushes, hair loss, and blurring of vision.
* <b style="color:red;">"Stair-step" CC Regimen</b>: If no follicle develops, the dose is increased immediately within the same cycle to avoid waiting for menses.
* <b style="color:red;">Letrozole</b>: An aromatase inhibitor; preferred over CC in <b style="color:red;">PCOS</b> patients due to higher live birth rates and lower multiple pregnancy rates.
* <b style="color:red;">Metformin</b>: An insulin-sensitizing biguanide used as an adjunct in <b style="color:red;">obese PCOS patients</b>; start "low and slow" to minimize GI side effects (nausea/vomiting).
* <b style="color:red;">Gonadotropins (FSH/HMG)</b>: Used when patients are unresponsive to CC/Letrozole; requires ultrasound monitoring to prevent <b style="color:red;">OHSS</b>.
* <b style="color:red;">HCG (5,000-10,000 IU)</b>: Used as a "trigger" to induce ovulation, which occurs 36-48 hours after administration.
* <b style="color:red;">Dopamine Agonists</b>: Specific treatment for anovulation caused by <b style="color:red;">Hyperprolactinemia</b>.

---

### <b><i style="color:red;">Ovarian Hyperstimulation Syndrome (OHSS)</i></b>

* <b style="color:red;">OHSS Pathogenesis</b>: Excessive ovarian stimulation leads to high E2 and VEGF secretion, causing increased vascular permeability and massive fluid shifts.
* <b style="color:red;">OHSS Mild</b>: Ovarian enlargement ≤5 cm with abdominal discomfort.
* <b style="color:red;">OHSS Moderate</b>: Ovarian enlargement 6-10 cm, nausea/GI symptoms, and <b style="color:red;">mild ascites</b> (not clinically evident).
* <b style="color:red;">OHSS Severe</b>: Clinically evident <b style="color:red;">ascites</b>, hydrothorax, hematocrit >45%, and increased WBC. Requires hospitalization.
* <b style="color:red;">OHSS Critical</b>: Oliguria, creatinine >1.6 mg/dL, <b style="color:red;">thrombosis</b>, infection, and potential DIC.
* <b style="color:red;">OHSS Prevention</b>: Use of GnRH agonist trigger instead of HCG, lowering gonadotropin doses, or "coasting."

---

### <b><i style="color:red;">In-Vitro Fertilization (IVF) Specifics</i></b>

* <b style="color:red;">IVF Indications</b>: Blocked tubes, severe male factor, advanced maternal age, unexplained infertility failed IUI, and genetic screening.
* <b style="color:red;">Intracytoplasmic Sperm Injection (ICSI)</b>: Single sperm injection into a mature oocyte; preferred for male factor infertility, prior failed fertilization, and frozen oocytes.
* <b style="color:red;">Oocyte Harvesting</b>: Performed 34-36 hours after HCG trigger; requires at least 3 mature follicles (≥18 mm) on ultrasound.
* <b style="color:red;">Embryo Transfer (Day 3 vs Day 5)</b>: <b style="color:red;">Blastocysts (Day 5)</b> have higher implantation and pregnancy rates than cleavage-stage (Day 3) embryos.
* <b style="color:red;">Assisted Hatching (AH)</b>: Drilling a hole in the zona pellucida with laser/acid; useful for older women (>37) but increases risk of <b style="color:red;">monozygotic twinning</b>.
* <b style="color:red;">Elective Single Embryo Transfer (eSET)</b>: Recommended for women <35 to minimize the risk of high-risk multifetal pregnancies.
* <b style="color:red;">In-Vitro Maturation (IVM)</b>: Harvesting immature eggs to mature them outside the body; primarily used in <b style="color:red;">PCOS</b> to eliminate OHSS risk.
* <b style="color:red;">Frozen Embryo Transfer (FET)</b>: Requires estrogen therapy to prime the endometrium and progesterone supplementation 4-6 days before transfer.
* <b style="color:red;">Recurrent Implantation Failure</b>: Defined as 3 failed transfers of good embryos or 2 failed transfers of euploid blastocysts; may require <b style="color:red;">Endometrial Receptivity Analysis (ERA)</b>.

---

### <b><i style="color:red;">Genetic Testing & Fertility Preservation</i></b>

* <b style="color:red;">PGT-A</b>: Genetic testing for <b style="color:red;">aneuploidy</b> (abnormal chromosome number); recommended for advanced maternal age (>37) or recurrent loss.
* <b style="color:red;">PGT-M</b>: Genetic testing for <b style="color:red;">monogenic diseases</b> (e.g., Cystic Fibrosis, Tay-Sachs, Huntington’s).
* <b style="color:red;">Trophectoderm Biopsy</b>: The preferred method for PGT, performed on Day 5 or 6 blastocysts.
* <b style="color:red;">Social Freezing</b>: Oocyte cryopreservation in healthy young women to delay childbearing and mitigate the age effect on fecundity.
* <b style="color:red;">GnRH agonist (in chemotherapy)</b>: Administered 7-10 days before chemo to protect ovaries by suppressing the HPG axis and reducing blood flow.
* <b style="color:red;">Ovarian tissue cryopreservation</b>: Option for cancer patients, but <b style="color:red;">contraindicated in leukemias</b> due to the risk of malignant cell re-seeding.

---

### <b><i style="color:red;">Differentiating Similar Entities & Exam High-Yield Points</i></b>

1. <b style="color:red;">Fecundability (20%)</b> is the *monthly* probability of pregnancy, whereas <b style="color:red;">Fecundity</b> is the *monthly* probability of a *live birth*.
2. <b style="color:red;">LH Test (First morning urine)</b> means ovulation is *now* (today); <b style="color:red;">LH Test (Random urine)</b> means ovulation is *tomorrow* (12-24 hours).
3. <b style="color:red;">Clomiphene Citrate</b> is an estrogen *receptor antagonist* (systemic); <b style="color:red;">Letrozole</b> is an *aromatase inhibitor* (inhibits conversion to estrogen).
4. <b style="color:red;">Letrozole</b> is superior to <b style="color:red;">Clomiphene</b> specifically in *PCOS* patients; they are roughly equal in unexplained infertility.
5. <b style="color:red;">Serum Progesterone >3 ng/mL</b> proves *ovulation* happened; <b style="color:red;">Serum Progesterone ≥10 ng/mL</b> is the threshold for *healthy spontaneous conception*.
6. <b style="color:red;">Hydrosalpinx vs. Salpingitis Isthmica Nodosa (SIN)</b>: Hydrosalpinx is *distal* ballooning; SIN is *proximal* nodular scarring (often from infection).
7. <b style="color:red;">IUI vs. IVF-ICSI</b>: IUI still requires *patent tubes* and decent sperm; IVF-ICSI can bypass blocked tubes and severe sperm counts.
8. <b style="color:red;">OHSS Moderate vs. Severe</b>: Moderate has *ascites on ultrasound only*; Severe has *clinically evident ascites* (distended abdomen) and hemoconcentration (Hct >45%).
9. <b style="color:red;">OHSS Severe vs. Critical</b>: Severe has ascites/effusions; Critical adds *organ failure* (Oliguria, Creatinine >1.6, or Thrombosis).
10. <b style="color:red;">Azoospermia (Obstructive vs. Non-obstructive)</b>: Obstructive (e.g., absent vas deferens) has a better prognosis for sperm retrieval than Non-obstructive (e.g., genetic failure).
11. <b style="color:red;">Y-Chromosome Microdeletions</b>: Sperm can be retrieved in *AZFb/AZFc* deletions, but *NOT* in *AZFa* deletions.
12. <b style="color:red;">AMH vs. FSH</b>: AMH is *cycle-independent* (can be taken anytime); FSH must be taken on *Day 2-3* to be accurate.
13. <b style="color:red;">Day 3 vs. Day 5 Embryo Transfer</b>: Day 3 are *cleavage-stage* (6-8 cells); Day 5 are *blastocysts* (ready for implantation).
14. <b style="color:red;">PGT-A vs. PGT-M</b>: PGT-A is for chromosomal quantity (e.g., Down Syndrome); PGT-M is for specific single-gene mutations (e.g., Cystic Fibrosis).
15. <b style="color:red;">Intramural Myoma >4 cm</b> decreases pregnancy rates; <b style="color:red;">Submucous Myoma</b> (any size) decreases pregnancy rates and requires removal.
16. <b style="color:red;">Oil-based vs. Water-based HSG contrast</b>: Oil-based potentially increases pregnancy rates but risk *granuloma*; Water-based is safer and more common.
17. <b style="color:red;">Endometrial Biopsy vs. ERA</b>: Endometrial biopsy for "dating" is obsolete; <b style="color:red;">ERA</b> is a modern genetic analysis used for recurrent implantation failure.
18. <b style="color:red;">Basal Body Temperature (BBT)</b> only confirms *that* ovulation happened after it occurred; it is *not* good for timing intercourse in the same cycle.
19. <b style="color:red;">Infertility Workup</b>: A single abnormal semen analysis is *not* diagnostic; it must be repeated after 4 weeks because sperm takes ~3 months to mature.
20. <b style="color:red;">GIFT vs. ZIFT</b>: GIFT is Gamete transfer (pre-fertilization) into the tube; ZIFT is Zygote transfer (post-fertilization) into the tube. Both are rarely used compared to IVF-ET.


## QA
text
### <b><i style="color:red;">Infertility and Assisted Reproductive Technology (ART) Overview</i></b>

1. What is the definition of <b><font color="red">Infertility</font></b>? | Inability to conceive <br>After 1 year of unprotected sex (6 months if >35).
2. What are the clinical manifestations of <b><font color="red">Infertility</font></b>? (3) | Oligo/amenorrhea, <br>Tubal obstruction, <br>Endometriosis
3. What is the diagnosis and work-up for <b><font color="red">Infertility</font></b>? | Comprehensive History and PE <br>Ancillary testing (Semen analysis, HSG).
4. What are the treatment options for <b><font color="red">Infertility</font></b>? (3) | Ovulation induction, <br>IUI, <br>IVF
5. What is the pathogenesis of <b><font color="red">Male Factor Infertility</font></b>? | Issues with sperm <br>Producton, motility, or morphology issues (25% of cases).
6. What are the clinical findings of <b><font color="red">Male Factor Infertility</font></b>? | Oligospermia or azoospermia <br>Low sperm count or absence of sperm.
7. What is the primary diagnostic tool for <b><font color="red">Male Factor Infertility</font></b>? | Semen Analysis <br>Based on WHO 2010 criteria.
8. What are the WHO 2010 criteria for <b><font color="red">Semen Analysis</font></b>? (4) | Vol ≥1.5mL, <br>Conc ≥15M/mL, <br>Motility ≥40%, <br>Morph ≥4%
9. What is the management for <b><font color="red">Male Factor Infertility</font></b>? | Lifestyle changes, IUI, or IVF-ICSI.
10. What is the pathogenesis of <b><font color="red">Ovulatory Disorders</font></b>? | HPO axis dysfunction <br>Leading to anovulation (27% of female factors).
11. What are the clinical manifestations of <b><font color="red">Ovulatory Disorders</font></b>? | Irregular cycles <br>Associated with low midluteal progesterone.
12. What diagnostic tests are used for <b><font color="red">Ovulatory Disorders</font></b>? (2) | Serum Progesterone <br>Basal Body Temperature (BBT)
13. What is the first-line treatment for <b><font color="red">Ovulatory Disorders</font></b>? | Clomiphene Citrate or Letrozole.
14. What are the common <b><font color="red">Tubal/Uterine Factors</font></b> in infertility? | Physical blockages <br>Structural abnormalities like hydrosalpinx or myomas.
15. How are <b><font color="red">Tubal/Uterine Factors</font></b> diagnosed? (2) | HSG and Laparoscopy. |
16. What is the management for <b><font color="red">Tubal/Uterine Factors</font></b>? | Tubal surgery, <br>Myomectomy, or IVF.
17. Define the pathogenesis of <b><font color="red">Endometriosis</font></b> in infertility. | Inflammatory disease <br>Affects 40% of infertile women.
18. What are the clinical manifestations of <b><font color="red">Endometriosis</font></b>? (3) | Pain, <br>Reduced fecundity, <br>Mechanical obstruction
19. What is the gold standard for <b><font color="red">Endometriosis</font></b> diagnosis? | Laparoscopy <br>Provides a visual diagnosis.
20. What is the treatment for infertility caused by <b><font color="red">Endometriosis</font></b>? | COS + IUI <br>IVF if no pregnancy after 3-6 cycles.
21. What is <b><font color="red">Ovarian Hyperstimulation Syndrome (OHSS)</font></b>? | Iatrogenic complication <br>Result of gonadotropin therapy.
22. What are clinical signs of <b><font color="red">OHSS</font></b>? (3) | Ovarian enlargement, <br>Ascites, <br>Hemoconcentration
23. How is <b><font color="red">OHSS</font></b> managed? | Supportive care <br>Fluids, electrolytes, and avoiding HCG trigger.

### <b><i style="color:red;">Definitions & Epidemiology</i></b>

24. Define <b><font color="red">Infertility</font></b> (General definition). | Inability to conceive <br>Within 1 year of unprotected sexual contact.
25. When is an <b><font color="red">Early Infertility evaluation</font></b> warranted (after 6 months)? (5) | Women >35, <br>Oligo/amenorrhea, <br>Tubal disease, <br>Endometriosis, <br>Male factors
26. What is <b><font color="red">Fecundability</font></b>? | Monthly pregnancy probability <br>Typically approximately 20% in fertile couples.
27. What percentage of infertility is due to <b><font color="red">Female Infertility factors</font></b>? | 54% of cases.
28. What are the two most common <b><font color="red">Female Infertility factors</font></b>? | Ovulatory (27%) and Tubal (22%).
29. What is <b><font color="red">Unexplained Infertility</font></b>? | Normal diagnostic tests <br>Occurs in 17-20% of couples.
30. How does <b><font color="red">Infertility prevalence</font></b> change for age 30-34? | 1 in 7 couples.
31. How does <b><font color="red">Infertility prevalence</font></b> change for age 35-40? | 1 in 5 couples.
32. How does <b><font color="red">Infertility prevalence</font></b> change for age 40-44? | 1 in 4 couples.
33. How does age affect pregnancy rates for <b><font color="red">Azoospermic husbands</font></b> using donor insemination? | Decreases with age <br>73% if <25 years; 55.8% if 36-40 years.
34. What is the most common diagnostic category in women undergoing <b><font color="red">IVF</font></b>? | Diminished Ovarian Reserve.

### <b><i style="color:red;">Physiology & Optimal Timing</i></b>

35. What is the <b><font color="red">Oocyte lifespan</font></b>? | Less than 24 hours <br>After reaching the ampulla.
36. What is the <b><font color="red">Sperm lifespan</font></b> in the oviduct? | Up to 72 hours.
37. What is the <b><font color="red">Optimal conception time</font></b>? | Day before ovulation <br>Or daily for 3 days at mid-cycle.
38. When does ovulation occur if <b><font color="red">LH Surge detection (First morning urine)</font></b> is positive? | Same day of detection.
39. When does ovulation occur if <b><font color="red">LH Surge detection (Random urine)</font></b> is positive? | 12 to 24 hours later <br>Technically the "suivant" or next day.
40. Name four <b><font color="red">Conception blockers</font></b>. | Vaginal lubricants, <br>Saliva, <br>Cigarette smoking, <br>Douching

### <b><i style="color:red;">Ovulation & Ovarian Reserve Assessment</i></b>

41. What <b><font color="red">Serum Progesterone</font></b> value suggests some ovulatory function? | >3-5 ng/mL.
42. What <b><font color="red">Serum Progesterone</font></b> value suggests a normal ovulatory cycle? | ≥10 ng/mL.
43. What is the physiological basis for <b><font color="red">Basal Body Temperature (BBT)</font></b> testing? | Thermogenic effect of progesterone <br>Acting on the hypothalamus.
44. What are the requirements for accurate <b><font color="red">BBT</font></b> measurement? | Sublingual temperature <br>Immediately after awakening after 6 hours sleep.
45. Why is <b><font color="red">Endometrial Biopsy</font></b> no longer indicated for routine workup? | Invasive and subjective <br>Formerly used for luteal phase defects.
46. Who should undergo <b><font color="red">Ovarian Reserve Testing</font></b>? (4) | Women >35, <br>Unexplained infertility, <br>Smokers, <br>History of ovarian surgery/chemo/radiation
47. What does an <b><font color="red">FSH level >10 mIU/mL</font></b> on Day 2 or 3 indicate? | Decreased ovarian reserve.
48. What does an <b><font color="red">FSH level >20 mIU/mL</font></b> indicate? | Poor prognosis for pregnancy.
49. What <b><font color="red">Serum Estradiol (E2)</font></b> level indicates a poor prognosis early in the cycle? | >70 pg/mL.
50. What is <b><font color="red">Anti-Müllerian Hormone (AMH)</font></b> produced by? | Granulosa cells.
51. What <b><font color="red">AMH</font></b> level indicates decreased ovarian reserve? | <0.5 ng/mL.
52. What <b><font color="red">AMH</font></b> level indicates many follicles are available? | >2 ng/mL.
53. What <b><font color="red">AMH</font></b> level predicts menopause within 4-5 years? | 0.05 ng/mL.
54. How is the <b><font color="red">Antral Follicle Count (AFC)</font></b> measured? | Transvaginal ultrasound (TVS) <br>On cycle day 2 to 4.
55. What <b><font color="red">Antral Follicle Count (AFC)</font></b> suggests good ovarian reserve? | 10 or more follicles <br>Follicles sized 2-10 mm.

### <b><i style="color:red;">Semen Analysis & Male Evaluation</i></b>

56. What is the required abstinence period for a <b><font color="red">Male Infertility workup</font></b>? | 2-3 days of abstinence.
57. When does <b><font color="red">Sperm motility</font></b> begin to decline after ejaculation? | After 2 hours.
58. What is the significance of <b><font color="red">Sperm morphology</font></b>? | Reflects production from 3 months prior <br>Subjective test using Kruger criteria.
59. What is the <b><font color="red">Kruger criteria</font></b> threshold for fertilization ability? | 4% normal forms.
60. What are the WHO 2010 <b><font color="red">Low normal sperm values</font></b>? (3) | 15 M/mL concentration, <br>39 M/ejaculate total, <br>40% motility
61. Why must <b><font color="red">Unwashed seminal fluid</font></b> NOT be used in IUI? | Causes severe uterine cramps <br>Contains prostaglandins and risk of infection.
62. In what condition is <b><font color="red">Intrauterine Insemination (IUI)</font></b> less successful? | Significant oligospermia <br><5 million motile sperm.

### <b><i style="color:red;">Hysterosalpingography (HSG) & Tubal Disease</i></b>

63. What is the optimal <b><font color="red">HSG Timing</font></b>? | 10th day of cycle <br>Ensures follicular phase/no pregnancy.
64. What are the <b><font color="red">HSG Contraindications</font></b>? (2) | Untreated salpingitis <br>Tenderness on pelvic exam.
65. Why is <b><font color="red">Water-soluble contrast</font></b> preferred in HSG? | Avoids peritoneal irritation <br>Prevents oil-induced granulomas.
66. When is <b><font color="red">Doxycycline</font></b> prophylaxis given for HSG? | If hydrosalpinx is visualized <br>100 mg BID for 1-2 weeks.
67. How does <b><font color="red">Hydrosalpinx</font></b> appear on HSG? | Distal blockage with ballooning <br>Sausage-like appearance with no dye spillage.
68. What causes <b><font color="red">Proximal Tubal Obstruction</font></b>? | True block (SIN, infection) <br>Or cornual spasm (false block).
69. Why is <b><font color="red">Laparoscopic Salpingectomy</font></b> recommended before IVF for large hydrosalpinx? | Fluid reduces success rates <br>Embryo implantation decreased by 40%.
70. What is the best prognostic factor for pregnancy after <b><font color="red">Tubal reconstructive surgery</font></b>? | Tubal wall thickness.
71. How does <b><font color="red">Tubal Tuberculosis</font></b> appear radiographically? | Pipe stem configuration.
72. What is the fertility prognosis for women with <b><font color="red">Pelvic Tuberculosis</font></b>? | Considered sterile.

### <b><i style="color:red;">Medical Management of Anovulation</i></b>

73. What is the mechanism of <b><font color="red">Clomiphene Citrate (CC)</font></b>? | Selective estrogen receptor antagonist.
74. What is the typical dose and timing for <b><font color="red">Clomiphene Citrate</font></b>? | 50-150 mg for 5 days <br>Starting on cycle day 3-5.
75. Name four <b><font color="red">Clomiphene side effects</font></b>. | Multiple gestations (8%), <br>Ovarian cysts, <br>Vasomotor flushes, <br>Blurring of vision
76. What is the <b><font color="red">"Stair-step" CC Regimen</font></b>? | Immediate dose increase <br>Used if no follicle develops within the same cycle.
77. What is the mechanism of <b><font color="red">Letrozole</font></b>? | Aromatase inhibitor.
78. Why is <b><font color="red">Letrozole</font></b> preferred for PCOS patients? | Higher live birth rates <br>Lower incidence of multiple pregnancy.
79. What is the role of <b><font color="red">Metformin</font></b> in infertility? | Adjunct for obese PCOS <br>Insulin-sensitizing biguanide.
80. When are <b><font color="red">Gonadotropins (FSH/HMG)</font></b> indicated? | Unresponsive to CC/Letrozole.
81. Why is ultrasound monitoring required for <b><font color="red">Gonadotropins</font></b>? | To prevent OHSS.
82. What is the function of <b><font color="red">HCG (5,000-10,000 IU)</font></b> in ART? | Trigger for ovulation <br>Occurs 36-48 hours after administration.
83. What is the treatment for anovulation due to <b><font color="red">Hyperprolactinemia</font></b>? | Dopamine Agonists.

### <b><i style="color:red;">Ovarian Hyperstimulation Syndrome (OHSS)</i></b>

84. What is the <b><font color="red">OHSS Pathogenesis</font></b>? | High E2 and VEGF secretion <br>Leads to vascular permeability/fluid shifts.
85. Define <b><font color="red">OHSS Mild</font></b>. | Ovarian enlargement ≤5 cm <br>Accompanied by abdominal discomfort.
86. Define <b><font color="red">OHSS Moderate</font></b>. | Ovarian enlargement 6-10 cm <br>Nausea and mild ascites (on ultrasound).
87. Define <b><font color="red">OHSS Severe</font></b>. | Clinically evident ascites/hydrothorax <br>Hematocrit >45% and high WBC.
88. Define <b><font color="red">OHSS Critical</font></b>. (4) | Oliguria, <br>Creatinine >1.6 mg/dL, <br>Thrombosis, <br>DIC
89. How is <b><font color="red">OHSS prevented</font></b> in ART? (3) | GnRH agonist trigger, <br>Lowering gonadotropin doses, <br>"Coasting"

### <b><i style="color:red;">In-Vitro Fertilization (IVF) Specifics</i></b>

90. List four <b><font color="red">IVF Indications</font></b>. | Blocked tubes, <br>Severe male factor, <br>Advanced maternal age, <br>Failed IUI
91. What is <b><font color="red">Intracytoplasmic Sperm Injection (ICSI)</font></b>? | Single sperm injection <br>Directly into a mature oocyte.
92. When is <b><font color="red">ICSI</font></b> preferred? (3) | Male factor, <br>Failed fertilization, <br>Frozen oocytes
93. When is <b><font color="red">Oocyte Harvesting</font></b> performed? | 34-36 hours after HCG trigger.
94. What are the ultrasound requirements for <b><font color="red">Oocyte Harvesting</font></b>? | ≥3 mature follicles <br>Size ≥18 mm.
95. Compare <b><font color="red">Embryo Transfer (Day 3 vs Day 5)</font></b>. | Day 5 (Blastocysts) <br>Higher implantation and pregnancy rates.
96. What is the risk associated with <b><font color="red">Assisted Hatching (AH)</font></b>? | Monozygotic twinning.
97. What is <b><font color="red">Elective Single Embryo Transfer (eSET)</font></b>? | Recommended for women <35 <br>To minimize high-risk multifetal pregnancies.
98. What is the advantage of <b><font color="red">In-Vitro Maturation (IVM)</font></b> in PCOS? | Eliminates OHSS risk <br>Harvests and matures immature eggs outside the body.
99. What does <b><font color="red">Frozen Embryo Transfer (FET)</font></b> require? | Estrogen therapy <br>And progesterone 4-6 days before transfer.
100. Define <b><font color="red">Recurrent Implantation Failure</font></b>. | 3 failed good embryo transfers <br>Or 2 failed euploid blastocyst transfers.
101. What test is used for <b><font color="red">Recurrent Implantation Failure</font></b>? | Endometrial Receptivity Analysis (ERA).

### <b><i style="color:red;">Genetic Testing & Fertility Preservation</i></b>

102. What is <b><font color="red">PGT-A</font></b>? | Testing for aneuploidy <br>Abnormal chromosome number.
103. What is <b><font color="red">PGT-M</font></b>? | Testing for monogenic diseases <br>e.g., Cystic Fibrosis, Tay-Sachs.
104. What is the preferred method for <b><font color="red">PGT Biopsy</font></b>? | Trophectoderm Biopsy <br>Performed on Day 5 or 6 blastocysts.
105. What is <b><font color="red">Social Freezing</font></b>? | Oocyte cryopreservation <br>To delay childbearing/delay age effect.
106. Why is a <b><font color="red">GnRH agonist</font></b> used during chemotherapy? | To protect ovaries <br>Suppresses HPG axis and reduces blood flow.
107. When is <b><font color="red">Ovarian tissue cryopreservation</font></b> contraindicated? | Leukemias <br>Risk of malignant cell re-seeding.

### <b><i style="color:red;">Differentiating Similar Entities & Exam High-Yield Points</i></b>

108. Compare <b><font color="red">Fecundability vs Fecundity</font></b>. | Fecundability: Monthly pregnancy probability (20%) <br>Fecundity: Monthly live birth probability.
109. Compare <b><font color="red">LH Test (First morning vs Random urine)</font></b> timing. | First morning: Ovulation today <br>Random: Ovulation tomorrow (12-24h).
110. Compare <b><font color="red">Clomiphene Citrate vs Letrozole</font></b> mechanism. | CC: Estrogen receptor antagonist <br>Letrozole: Aromatase inhibitor.
111. Compare <b><font color="red">Letrozole vs Clomiphene</font></b> in PCOS. | Letrozole is superior <br>Higher live birth rates.
112. Compare <b><font color="red">Serum Progesterone levels (>3 vs ≥10 ng/mL)</font></b>. | >3: Confirms ovulation <br>≥10: Threshold for healthy conception.
113. Compare <b><font color="red">Hydrosalpinx vs SIN</font></b> location. | Hydrosalpinx: Distal ballooning <br>SIN: Proximal nodular scarring.
114. Compare <b><font color="red">IUI vs IVF-ICSI</font></b> requirements. | IUI: Patent tubes/decent sperm <br>IVF-ICSI: Can bypass blocked tubes/severe male factor.
115. Compare <b><font color="red">OHSS Moderate vs Severe</font></b> (Ascites). | Moderate: Ascites on U/S only <br>Severe: Clinically evident ascites.
116. Contrast <b><font color="red">OHSS Severe vs Critical</font></b>. | Critical adds organ failure <br>Creatinine >1.6 or thrombosis.
117. Compare <b><font color="red">Azoospermia (Obstructive vs Non-obstructive)</font></b> prognosis. | Obstructive has better sperm retrieval prognosis <br>e.g., absent vas deferens vs genetic failure.
118. Can sperm be retrieved in <b><font color="red">Y-Chromosome Microdeletions</font></b>? | Yes in AZFb/AZFc <br>No in AZFa deletions.
119. Compare <b><font color="red">AMH vs FSH</font></b> cycle timing. | AMH: Cycle-independent <br>FSH: Must be Day 2-3.
120. Compare <b><font color="red">Day 3 vs Day 5 Embryos</font></b>. | Day 3: Cleavage-stage (6-8 cells) <br>Day 5: Blastocysts.
121. Compare <b><font color="red">PGT-A vs PGT-M</font></b> targets. | PGT-A: Chromosomal quantity <br>PGT-M: Specific single-gene mutations.
122. Compare <b><font color="red">Intramural vs Submucous Myoma</font></b>. | Intramural (>4cm): Decreases rate <br>Submucous (any size): Decreases rate/requires removal.
123. Compare <b><font color="red">Oil-based vs Water-based HSG contrast</font></b>. | Oil: Potential pregnancy increase/risk granuloma <br>Water: Safer and more common.
124. Compare <b><font color="red">Endometrial Biopsy vs ERA</font></b>. | Biopsy: Obsolete for dating <br>ERA: Modern genetic analysis for implantation failure.
125. Why is <b><font color="red">Basal Body Temperature (BBT)</font></b> bad for timing? | Only confirms ovulation occurred <br>Retroactive confirmation only.
126. Why is one <b><font color="red">Semen analysis</font></b> result not diagnostic? | Sperm takes 3 months to mature <br>Must repeat after 4 weeks.
127. Compare <b><font color="red">GIFT vs ZIFT</font></b>. | GIFT: Gametes into tube <br>ZIFT: Zygote into tube.


---
# 2
## Summary
text
### <b><i style="color:red;">I. Overview of Immunologic Response</i></b>

| Feature | <b><font color="red">Innate Immunity</font></b> | <b><font color="red">Adaptive Immunity</font></b> |
| :--- | :--- | :--- |
| <b>Specificity</b> | Non-specific; recognizes broad patterns (PAMPs). | Highly specific to unique pathogens/antigens. |
| <b>Memory</b> | No immunologic memory; response same on re-exposure. | Memory-based; response increases with repeated exposure. |
| <b>Components</b> | Epithelial barriers, Macrophages, NK cells, Neutrophils, Dendritic cells, Complement. | T cells (Cell-mediated) and B cells (Humoral). |
| <b>Response Time</b> | Rapid, first line of defense. | Slower initial response; highly effective later. |

* <b><font color="red">Pattern Recognition Receptors (PRRs)</font></b> are germline-encoded receptors on effector cells that detect <b>Pathogen-Associated Molecular Patterns (PAMPs)</b> on microbes to trigger inflammation. 
* <b><font color="red">Toll-Like Receptors (TLRs)</font></b> are a type of PRR that stimulates <b>type 1 interferon (IFN)</b>, which possesses antimicrobial, antiviral, and anticancer properties.
* <b><font color="red">Natural Killer (NK) Cells</font></b> are very important in cancer management; they directly kill infected or tumor cells that lack <b>MHC class I molecules</b>.
* <b><font color="red">Complement System</font></b> activation leads to <b>C3 cleavage</b> and the formation of membrane pores via <b>C6, C7, C8, and C9 proteins</b>, resulting in cell lysis.
* <b><font color="red">Humoral Immunity (B cells)</font></b> involves <b>B cells</b> originating in the bone marrow and differentiating into plasma cells to secrete antibodies (immunoglobulins).
* <b><font color="red">Antibody Structure</font></b> consists of two heavy and two light chains; the <b>Variable (V) region</b> provides antigen specificity, while the <b>Constant (C) region</b> binds to phagocytes.
* <b><font color="red">IgM</font></b> is the first antibody produced in an immune response and is a potent activator of the complement system.
* <b><font color="red">IgG</font></b> serves in the later immune response, provides <b>neonatal immunity</b> via placental transfer, and coats antigens for phagocytosis (opsonization).
* <b><font color="red">Cellular Immunity (T cells)</font></b> requires direct cell-to-cell contact and recognizes peptide antigens only when presented on <b>MHC molecules</b>.
* <b><font color="red">Class I MHC</font></b> is found on <b>all nucleated cells</b> and activates <b>CD8+ Cytotoxic T Lymphocytes (CTLs)</b> to destroy tumor or infected cells.
* <b><font color="red">Class II MHC</font></b> is found only on <b>Antigen-Presenting Cells (APCs)</b> and activates <b>CD4+ Helper T cells</b>.
* <b><font color="red">Regulatory T Cells (Tregs)</font></b> are CD4+ T cells that suppress the immune response; in cancer, they may prevent the immune system from recognizing tumor "self-antigens."
* <b><font color="red">Th1 Cells</font></b> secrete IL-2 and IFN-γ to promote cell-mediated inflammatory responses, while <b><font color="red">Th2 Cells</font></b> secrete IL-4, IL-5, IL-6, and IL-10 to promote antibody production.

### <b><i style="color:red;">II. Cancer Immunity Cycle & Immunotypes</i></b>

* <b>The <font color="red">Cancer Immunity Cycle</font></b> is a 7-step iterative process: 1) Release of antigens, 2) Antigen presentation, 3) Priming/Activation, 4) Trafficking to tumors, 5) Infiltration, 6) Recognition, and 7) Killing of cancer cells.
* <b><font color="red">Immune Desert</font></b> immunotype is characterized by a complete paucity of immune cells within the tumor microenvironment (TME).
* <b><font color="red">Immune Excluded</font></b> immunotype occurs when T cells are present in the stroma but are prevented from migrating into the actual cancer cell nests by inhibitory barriers.
* <b><font color="red">Inflamed Tumors</font></b> contain stimulatory immune cells and tumor-infiltrating lymphocytes (TILs), which increase functional killing of cancer cells.
* <b><font color="red">Stimulatory Factors (Green)</font></b> in the cancer cycle include <b>IFN-α, IL-2, and TLR agonists</b>; their presence is used for monitoring and prognostication.
* <b><font color="red">Inhibitory Factors (Red)</font></b> such as <b>PD-L1, CTLA-4, and VEGF</b> help cancer cells evade the immune response and are targets for immunotherapy medications.
* <b><font color="red">CAR-T Therapy</font></b> involves genetically modifying a patient's T cells to express <b>Chimeric Antigen Receptors</b> targeting specific tumor antigens like mesothelin or MUC16.

### <b><i style="color:red;">III. Cytokines in Oncology</i></b>

| Category | <b><font color="red">Cytokine(s)</font></b> | <b>Primary Function in Oncology</b> |
| :--- | :--- | :--- |
| <b>Innate Immunity</b> | <b>IL-1, IL-12, IL-18, IL-23, TNF, IFN</b> | Mediate rapid, non-specific response; <b>IL-12</b> links innate and adaptive immunity. |
| <b>Adaptive Immunity</b> | <b>IL-2, IL-4, IL-5, IL-13, TGF-β, IFN-γ</b> | Clonal expansion of T cells (IL-2); Th1/Th2 differentiation; <b>TGF-β</b> aids tumor evasion. |
| <b>Hematopoiesis</b> | <b>G-CSF, GM-CSF, IL-3, Erythropoietin (EPO)</b> | Regulate bone marrow production; <b>G-CSF</b> is used to manage chemo-induced neutropenia. |

* <b><font color="red">M1 Macrophages</font></b> secrete stimulatory cytokines (IL-12, TNF-α) to promote immunity against tumors.
* <b><font color="red">M2 Macrophages</font></b> produce immunosuppressive factors (VEGF, IL-10, PGE2) that assist established tumors in growing and evading the immune system.
* <b><font color="red">Type I Interferons (IFN-α/β)</font></b> are stimulated by TLRs to inhibit viral replication and increase Class I MHC expression.
* <b><font color="red">Type II Interferon (IFN-γ)</font></b> is produced by T cells/NK cells to activate macrophages and promote the Th1 (cellular immunity) pathway.
* <b><font color="red">TGF-β</font></b> inhibits T-cell proliferation and is a major contributor to tumor immune evasion.
* <b><font color="red">Chemokines</font></b> are small proteins that regulate leukocyte infiltration, promote angiogenesis, and control site-specific metastasis.

### <b><i style="color:red;">IV. Molecular Oncology: Oncogenes & Tumor Suppressors</i></b>

* <b><font color="red">Oncogenes</font></b> are mutated derivatives of normal genes that result in a <b>GAIN OF FUNCTION</b>; alteration mechanisms include gene amplification, translocation, and overexpression.
* <b><font color="red">Tumor Suppressor Genes</font></b> control cell growth and proliferation; cancer develops following a <b>LOSS OF FUNCTION</b> (inactivation of both alleles).
* <b><font color="red">p53</font></b> is the "gate keeper of the genome" and the most common deregulated tumor suppressor; located on <b>chromosome 17</b>, it triggers apoptosis (via BAX, bcl-2) in response to DNA damage.
* <b><font color="red">PTEN (Phosphatase and tensin homologue)</font></b> is a tumor suppressor on <b>chromosome 10</b> that is mutated in 50% of endometrioid endometrial cancers and 20% of endometrial hyperplasias.
* <b><font color="red">Retinoblastoma (Rb) Gene</font></b> regulates G1 phase arrest; its inactivation follows <b>Knudson’s "two-hit" theory</b> (one inherited mutation, one somatic).
* <b><font color="red">HPV E6 Oncoprotein</font></b> (types 16/18) targets <b>p53</b> for degradation, while <b><font color="red">HPV E7 Oncoprotein</font></b> binds to <b>Rb</b> to upregulate cell proliferation in cervical cancer.
* <b><font color="red">Somatic Mutations</font></b> occur after conception in any body cell except germ cells and are <b>not passed to offspring</b>.
* <b><font color="red">Germline Mutations</font></b> occur in reproductive cells (egg/sperm) and are incorporated into the DNA of <b>every cell</b> in the offspring.

### <b><i style="color:red;">V. BRCA Genes & PARP Inhibitors</i></b>

* <b><font color="red">BRCA1 Gene</font></b> is located on <b>chromosome 17q21</b>; mutation carriers have a <b>40-50%</b> risk of ovarian cancer by age 70.
* <b><font color="red">BRCA2 Gene</font></b> is located on <b>chromosome 13q12.3</b>; carries a <b>20-25%</b> ovarian cancer risk and is linked to male breast, pancreatic, and biliary cancers.
* <b><font color="red">BRCA Genetic Testing</font></b> is indicated for nonmucinous epithelial ovarian cancer at any age, or breast cancer before age 50 with a strong family history.
* <b><font color="red">PARP Inhibitors</font></b> (e.g., <b>Olaparib, Rucaparib, Niraparib</b>) kill BRCA-deficient cells by causing an accumulation of DNA double-strand breaks that the cells cannot repair.
* <b>The <font color="red">SOLO-1 Trial</font></b> demonstrated that Olaparib maintenance therapy reduces disease progression or death by 70% in BRCA-mutated ovarian cancer.

### <b><i style="color:red;">VI. DNA Mismatch Repair (MMR) & Lynch Syndrome</i></b>

* <b><font color="red">Mismatch Repair (MMR) Deficiency</font></b> leads to <b>Microsatellite Instability (MSI)</b>; it is found in over 30% of endometrial cancers.
* <b>The <font color="red">MMR Repair Pathway</font></b> involves the <b>MutS complex</b> (recognition), <b>MutL</b> (excision), and re-synthesis of DNA strands.
* <b><font color="red">Lynch Syndrome (HNPCC)</font></b> is an autosomal dominant syndrome caused by germline mutations in MMR genes (<b>MSH2, MLH1, MSH6, PMS2</b>) predisposing to colorectal and endometrial cancers.
* <b><font color="red">MSH2 (Chr 2)</font></b> and <b><font color="red">MLH1 (Chr 3)</font></b> are the most common mutations in Lynch Syndrome.
* <b>The <font color="red">Amsterdam Criteria II</font></b> for Lynch diagnosis (the "3-2-1" rule): <b>3</b> relatives with HNPCC cancer (one being a 1st-degree relative of others), <b>2</b> successive generations, and <b>1</b> diagnosed before age 50.
* <b>The <font color="red">Bethesda Guidelines</font></b> are more sensitive than Amsterdam for identifying patients needing MSI testing, including those with colorectal/uterine cancer diagnosed under age 50.
* <b><font color="red">Immunotherapy (e.g., Dostarlimab)</font></b> is highly effective for <b>dMMR/MSI-H</b> recurrent or advanced endometrial cancer.

### <b><i style="color:red;">VII. Recent Advances & Local (Philippine) Context</i></b>

* <b><font color="red">CloneSeq-SV</font></b> is a new technique used in high-grade serous ovarian cancer (HGSOC) to track clonal evolution and drug resistance markers (e.g., CCNE1, MYC) using cell-free DNA.
* <b><font color="red">High-Grade Serous Ovarian Cancer (HGSOC)</font></b> drug resistance is often pre-existing at diagnosis, leading to clonal selection during treatment.
* <b><font color="red">AI-Based Biomarkers</font></b> use deep learning to quantify TILs or PD-L1/HER2 expression from digitized pathology slides.
* <b>In the <font color="red">Philippines</font></b>, cervical cancer is the most common gynecologic malignancy, and research is currently focusing on <b>PD-L1 expression</b> for immunotherapy.
* <b><font color="red">Neoadjuvant Olaparib</font></b> is being studied for advanced BRCA-mutated ovarian cancer patients who are ineligible for primary surgery.
* <b><font color="red">Philippine Gynecologic Oncology Research Group (PGOG)</font></b> conducts multi-center trials to improve local data on gynecologic cancers.

### <b><i style="color:red;">VIII. Comparison of Similar Entities for Exams</i></b>

1. <b><font color="red">Innate vs. Adaptive Immunity</font></b>: Innate is rapid and non-specific with no memory; Adaptive is slow-onset, highly specific, and possesses immunologic memory.
2. <b><font color="red">MHC Class I vs. MHC Class II</font></b>: MHC I is on all nucleated cells (presents to CD8+ T cells); MHC II is only on APCs (presents to CD4+ T cells).
3. <b><font color="red">Oncogenes vs. Tumor Suppressor Genes</font></b>: Oncogenes result from a <b>Gain of Function</b> (one allele mutated); Tumor Suppressors result from a <b>Loss of Function</b> (both alleles must be inactivated).
4. <b><font color="red">BRCA1 vs. BRCA2</font></b>: BRCA1 is on <b>Chr 17</b> (higher ovarian risk ~50%); BRCA2 is on <b>Chr 13</b> (lower ovarian risk ~20% and associated with male breast/pancreatic cancer).
5. <b><font color="red">Amsterdam I vs. Amsterdam II Criteria</font></b>: Amsterdam I only included colorectal cancer; Amsterdam II was revised to include <b>extracolonic HNPCC cancers</b> (endometrial, small bowel, ureter, etc.).
6. <b><font color="red">Bethesda vs. Amsterdam II Criteria</font></b>: Bethesda is <b>more sensitive</b> (catches more potential Lynch cases); Amsterdam II is <b>more specific</b> (higher certainty if criteria are met).
7. <b><font color="red">M1 vs. M2 Macrophages</font></b>: M1 promotes tumor <b>killing</b> (pro-inflammatory); M2 promotes tumor <b>growth/evasion</b> (immunosuppressive).
8. <b><font color="red">Somatic vs. Germline Mutation</font></b>: Somatic is <b>not heritable</b> (occurs after conception); Germline is <b>heritable</b> (present in reproductive cells and every cell of offspring).
9. <b><font color="red">Th1 vs. Th2 Cells</font></b>: Th1 promotes <b>cell-mediated</b> immunity (IFN-γ); Th2 promotes <b>humoral/antibody</b> immunity (IL-4).
10. <b><font color="red">IgG vs. IgM</font></b>: IgG crosses the <b>placenta</b> and is part of the late/memory response; IgM is the <b>first</b> produced and stays in the vascular space (pentamer).
11. <b><font color="red">HPV E6 vs. HPV E7</font></b>: E6 degrades <b>p53</b>; E7 binds/inactivates <b>Rb</b>.
12. <b><font color="red">Immune Desert vs. Immune Excluded</font></b>: In "Desert," immune cells are absent from the TME; in "Excluded," immune cells exist in the stroma but cannot penetrate the tumor nest.
13. <b><font color="red">G-CSF vs. Erythropoietin (EPO)</font></b>: G-CSF stimulates <b>neutrophil</b> production (innate); EPO stimulates <b>red blood cell</b> production.
14. <b><font color="red">Cytotoxic T-cells (CTLs) vs. Natural Killer (NK) Cells</font></b>: CTLs require MHC presentation to recognize targets; NK cells kill targets specifically because they <b>lack</b> MHC I expression.
15. <b><font color="red">MSI-H vs. dMMR</font></b>: MSI-H (High Microsatellite Instability) is the <b>phenotype/effect</b>; dMMR (deficient Mismatch Repair) is the <b>mechanism/cause</b>.


## QA
code
### <b><i style="color:red;">I. Overview of Immunologic Response</i></b>

1. Describe the specificity of <b><font color="red">Innate Immunity</font></b>. | Non-specific; recognizes broad patterns (PAMPs).
2. Describe the specificity of <b><font color="red">Adaptive Immunity</font></b>. | Highly specific to unique pathogens/antigens.
3. Does <b><font color="red">Innate Immunity</font></b> possess immunologic memory? | No immunologic memory.
4. How does the response of <b><font color="red">Adaptive Immunity</font></b> change on re-exposure? | Response increases with repeated exposure.
5. List the components of <b><font color="red">Innate Immunity</font></b>. (6) | 1) Epithelial barriers <br>2) Macrophages <br>3) NK cells <br>4) Neutrophils <br>5) Dendritic cells <br>6) Complement
6. List the components of <b><font color="red">Adaptive Immunity</font></b>. (2) | 1) T cells (Cell-mediated) <br>2) B cells (Humoral)
7. Compare the response time of <b><font color="red">Innate vs. Adaptive Immunity</font></b>. | Innate is rapid/first line; Adaptive is slower initially.
8. Define <b><font color="red">Pattern Recognition Receptors (PRRs)</font></b>. | Germline-encoded receptors detecting PAMPs.
9. What is the role of <b><font color="red">Pattern Recognition Receptors (PRRs)</font></b> in the immune response? | Trigger inflammation.
10. What are <b><font color="red">Pathogen-Associated Molecular Patterns (PAMPs)</font></b>? | Broad patterns on microbes detected by PRRs.
11. What type of PRR stimulates <b><font color="red">Type 1 Interferon (IFN)</font></b>? | Toll-Like Receptors (TLRs).
12. List the three properties of <b><font color="red">Type 1 Interferon (IFN)</font></b>. | Antimicrobial, antiviral, and anticancer.
13. Why are <b><font color="red">Natural Killer (NK) Cells</font></b> important in cancer management? | Kill cells lacking MHC class I molecules.
14. Which cells do <b><font color="red">Natural Killer (NK) Cells</font></b> directly kill? | Infected or tumor cells.
15. What event occurs first in the <b><font color="red">Complement System</font></b> activation? | C3 cleavage.
16. Which proteins form membrane pores in the <b><font color="red">Complement System</font></b>? | C6, C7, C8, and C9.
17. What is the final result of membrane pore formation by the <b><font color="red">Complement System</font></b>? | Cell lysis.
18. Where do B cells in <b><font color="red">Humoral Immunity</font></b> originate? | Bone marrow.
19. What do B cells differentiate into to secrete antibodies in <b><font color="red">Humoral Immunity</font></b>? | Plasma cells.
20. Describe the basic <b><font color="red">Antibody Structure</font></b>. | Two heavy and two light chains.
21. What is the function of the <b><font color="red">Variable (V) region</font></b> of an antibody? | Provides antigen specificity.
22. What is the function of the <b><font color="red">Constant (C) region</font></b> of an antibody? | Binds to phagocytes.
23. Which antibody is the first produced in an <b><font color="red">Immune Response</font></b>? | IgM.
24. What system is <b><font color="red">IgM</font></b> a potent activator of? | Complement system.
25. What is the role of <b><font color="red">IgG</font></b> in the immune response? | Serves in the later immune response.
26. How does <b><font color="red">IgG</font></b> provide neonatal immunity? | Placental transfer.
27. Define Opsonization by <b><font color="red">IgG</font></b>. | Coating antigens for phagocytosis.
28. What does <b><font color="red">Cellular Immunity (T cells)</font></b> require for activation? | Direct cell-to-cell contact.
29. When do T cells recognize <b><font color="red">Peptide Antigens</font></b>? | Only when presented on MHC molecules.
30. Where is <b><font color="red">Class I MHC</font></b> found? | All nucleated cells.
31. Which cells are activated by <b><font color="red">Class I MHC</font></b>? | CD8+ Cytotoxic T Lymphocytes (CTLs).
32. What is the target of <b><font color="red">CD8+ Cytotoxic T Lymphocytes (CTLs)</font></b>? | Tumor or infected cells.
33. Where is <b><font color="red">Class II MHC</font></b> found? | Antigen-Presenting Cells (APCs).
34. Which cells are activated by <b><font color="red">Class II MHC</font></b>? | CD4+ Helper T cells.
35. What is the function of <b><font color="red">Regulatory T Cells (Tregs)</font></b>? | Suppress the immune response.
36. Identify the markers for <b><font color="red">Regulatory T Cells (Tregs)</font></b>. | CD4+.
37. How do <b><font color="red">Regulatory T Cells (Tregs)</font></b> assist cancer cells? | Prevent recognition of tumor "self-antigens."
38. What cytokines are secreted by <b><font color="red">Th1 Cells</font></b>? (2) | IL-2 and IFN-γ.
39. What type of response is promoted by <b><font color="red">Th1 Cells</font></b>? | Cell-mediated inflammatory responses.
40. What cytokines are secreted by <b><font color="red">Th2 Cells</font></b>? (4) | IL-4, IL-5, IL-6, and IL-10.
41. What is the primary function of <b><font color="red">Th2 Cells</font></b>? | Promote antibody production.

### <b><i style="color:red;">II. Cancer Immunity Cycle & Immunotypes</i></b>

42. How many steps are in the <b><font color="red">Cancer Immunity Cycle</font></b>? | 7 steps.
43. List the first three steps of the <b><font color="red">Cancer Immunity Cycle</font></b>. | 1) Release of antigens <br>2) Antigen presentation <br>3) Priming/Activation
44. List the last four steps of the <b><font color="red">Cancer Immunity Cycle</font></b>. | 4) Trafficking <br>5) Infiltration <br>6) Recognition <br>7) Killing
45. Describe the <b><font color="red">Immune Desert</font></b> immunotype. | Complete paucity of immune cells.
46. Where are T cells located in the <b><font color="red">Immune Excluded</font></b> immunotype? | In the stroma.
47. What prevents T cell migration in <b><font color="red">Immune Excluded</font></b> tumors? | Inhibitory barriers.
48. What are the components of <b><font color="red">Inflamed Tumors</font></b>? | Stimulatory immune cells and TILs.
49. What is the effect of <b><font color="red">Tumor-Infiltrating Lymphocytes (TILs)</font></b> in inflamed tumors? | Increase functional killing of cancer cells.
50. List the <b><font color="red">Stimulatory Factors (Green)</font></b> in the cancer cycle. (3) | IFN-α, IL-2, and TLR agonists.
51. What is the clinical use of <b><font color="red">Stimulatory Factors</font></b>? | Monitoring and prognostication.
52. List <b><font color="red">Inhibitory Factors (Red)</font></b> in cancer immunity. (3) | PD-L1, CTLA-4, and VEGF.
53. What is the purpose of <b><font color="red">Inhibitory Factors</font></b> for a tumor? | Evade the immune response.
54. Define <b><font color="red">CAR-T Therapy</font></b>. | Genetically modifying T cells with Chimeric Antigen Receptors.
55. Name two specific tumor antigens targeted by <b><font color="red">CAR-T Therapy</font></b>. | Mesothelin or MUC16.

### <b><i style="color:red;">III. Cytokines in Oncology</i></b>

56. Which cytokines mediate <b><font color="red">Innate Immunity</font></b>? (5) | IL-1, IL-12, IL-18, IL-23, TNF, IFN.
57. Which cytokine links <b><font color="red">Innate and Adaptive Immunity</font></b>? | IL-12.
58. List cytokines associated with <b><font color="red">Adaptive Immunity</font></b>. (6) | IL-2, IL-4, IL-5, IL-13, TGF-β, IFN-γ.
59. What is the function of <b><font color="red">IL-2</font></b> in adaptive immunity? | Clonal expansion of T cells.
60. Which cytokine aids <b><font color="red">Tumor Evasion</font></b> in adaptive immunity? | TGF-β.
61. List cytokines involved in <b><font color="red">Hematopoiesis</font></b>. (4) | G-CSF, GM-CSF, IL-3, Erythropoietin (EPO).
62. What is the clinical use of <b><font color="red">G-CSF</font></b>? | Manage chemo-induced neutropenia.
63. What do <b><font color="red">M1 Macrophages</font></b> secrete? | IL-12 and TNF-α.
64. What is the role of <b><font color="red">M1 Macrophages</font></b>? | Promote immunity against tumors.
65. What do <b><font color="red">M2 Macrophages</font></b> produce? (3) | VEGF, IL-10, PGE2.
66. How do <b><font color="red">M2 Macrophages</font></b> assist tumors? | Growth and immune evasion.
67. What stimulates <b><font color="red">Type I Interferons (IFN-α/β)</font></b>? | Toll-Like Receptors (TLRs).
68. What are the two main functions of <b><font color="red">Type I Interferons</font></b>? | 1) Inhibit viral replication <br>2) Increase Class I MHC.
69. Which cells produce <b><font color="red">Type II Interferon (IFN-γ)</font></b>? | T cells and NK cells.
70. What is the role of <b><font color="red">Type II Interferon (IFN-γ)</font></b>? | Activate macrophages and promote Th1.
71. How does <b><font color="red">TGF-β</font></b> impact T-cells? | Inhibits T-cell proliferation.
72. Define the role of <b><font color="red">Chemokines</font></b> in oncology. (3) | 1) Leukocyte infiltration <br>2) Angiogenesis <br>3) Metastasis.

### <b><i style="color:red;">IV. Molecular Oncology: Oncogenes & Tumor Suppressors</i></b>

73. Define <b><font color="red">Oncogenes</font></b>. | Mutated genes causing Gain of Function.
74. List mechanisms of <b><font color="red">Oncogene</font></b> alteration. (3) | Gene amplification, translocation, overexpression.
75. Define <b><font color="red">Tumor Suppressor Genes</font></b>. | Genes that control cell growth.
76. What mechanism causes cancer via <b><font color="red">Tumor Suppressor Genes</font></b>? | Loss of Function (inactivation of both alleles).
77. What is the nickname for <b><font color="red">p53</font></b>? | Gate keeper of the genome.
78. Where is the <b><font color="red">p53</font></b> gene located? | Chromosome 17.
79. How does <b><font color="red">p53</font></b> trigger apoptosis? | Via BAX and bcl-2.
80. Where is <b><font color="red">PTEN</font></b> located? | Chromosome 10.
81. In what percentage of <b><font color="red">Endometrioid Endometrial Cancers</font></b> is PTEN mutated? | 50%.
82. What does the <b><font color="red">Retinoblastoma (Rb) Gene</font></b> regulate? | G1 phase arrest.
83. Define <b><font color="red">Knudson’s "two-hit" theory</font></b> for Rb. | One inherited mutation, one somatic.
84. What is the target of <b><font color="red">HPV E6 Oncoprotein</font></b>? | p53 degradation.
85. What is the target of <b><font color="red">HPV E7 Oncoprotein</font></b>? | Binding/inactivation of Rb.
86. Define <b><font color="red">Somatic Mutations</font></b> heritability. | Not passed to offspring.
87. Where do <b><font color="red">Germline Mutations</font></b> occur? | Reproductive cells (egg/sperm).
88. Which cells contain the mutation in <b><font color="red">Germline Mutations</font></b>? | Every cell in the offspring.

### <b><i style="color:red;">V. BRCA Genes & PARP Inhibitors</i></b>

89. Where is the <b><font color="red">BRCA1 Gene</font></b> located? | Chromosome 17q21.
90. What is the ovarian cancer risk for <b><font color="red">BRCA1</font></b> carriers by age 70? | 40-50%.
91. Where is the <b><font color="red">BRCA2 Gene</font></b> located? | Chromosome 13q12.3.
92. What is the ovarian cancer risk for <b><font color="red">BRCA2</font></b> carriers? | 20-25%.
93. List non-breast/ovarian cancers linked to <b><font color="red">BRCA2</font></b>. (3) | Male breast, pancreatic, biliary.
94. When is <b><font color="red">BRCA Genetic Testing</font></b> indicated for ovarian cancer? | Nonmucinous epithelial at any age.
95. When is <b><font color="red">BRCA Genetic Testing</font></b> indicated for breast cancer? | Before age 50 with family history.
96. Provide three examples of <b><font color="red">PARP Inhibitors</font></b>. | Olaparib, Rucaparib, Niraparib.
97. How do <b><font color="red">PARP Inhibitors</font></b> kill BRCA-deficient cells? | Accumulation of DNA double-strand breaks.
98. What was the outcome of the <b><font color="red">SOLO-1 Trial</font></b>? | Olaparib reduced progression/death by 70%.

### <b><i style="color:red;">VI. DNA Mismatch Repair (MMR) & Lynch Syndrome</i></b>

99. What does <b><font color="red">Mismatch Repair (MMR) Deficiency</font></b> lead to? | Microsatellite Instability (MSI).
100. Percentage of <b><font color="red">Endometrial Cancers</font></b> with MMR deficiency? | Over 30%.
101. Match <b><font color="red">MutS and MutL</font></b> to their functions. | MutS (recognition); MutL (excision).
102. What is <b><font color="red">Lynch Syndrome (HNPCC)</font></b>? | Autosomal dominant germline MMR mutation.
103. List the four <b><font color="red">MMR Genes</font></b> mutated in Lynch Syndrome. | MSH2, MLH1, MSH6, PMS2.
104. Which two mutations are most common in <b><font color="red">Lynch Syndrome</font></b>? | MSH2 and MLH1.
105. State the "3-2-1" rule of <b><font color="red">Amsterdam Criteria II</font></b>. | 3 relatives, 2 generations, 1 diagnosed <50.
106. Explain the "3" in the <b><font color="red">Amsterdam Criteria II</font></b>. | 3 relatives with HNPCC cancer.
107. What is the advantage of <b><font color="red">Bethesda Guidelines</font></b> over Amsterdam? | More sensitive for identifying MSI testing.
108. Which drug is used for <b><font color="red">dMMR/MSI-H</font></b> recurrent endometrial cancer? | Dostarlimab.

### <b><i style="color:red;">VII. Recent Advances & Local (Philippine) Context</i></b>

109. What is <b><font color="red">CloneSeq-SV</font></b> used for? | Track clonal evolution using cell-free DNA.
110. List two drug resistance markers tracked by <b><font color="red">CloneSeq-SV</font></b>. | CCNE1 and MYC.
111. When is drug resistance typically present in <b><font color="red">HGSOC</font></b>? | Pre-existing at diagnosis.
112. How do <b><font color="red">AI-Based Biomarkers</font></b> assist pathology? | Quantify TILs or PD-L1/HER2 expression.
113. What is the most common gynecologic malignancy in the <b><font color="red">Philippines</font></b>? | Cervical cancer.
114. What is the research focus for Philippine cervical cancer? | PD-L1 expression.
115. Who is eligible for <b><font color="red">Neoadjuvant Olaparib</font></b> study? | Advanced BRCA-mutated, surgical ineligible.
116. What is the <b><font color="red">PGOG</font></b>? | Philippine Gynecologic Oncology Research Group.

### <b><i style="color:red;">VIII. Comparison of Similar Entities</i></b>

117. Compare <b><font color="red">Innate vs. Adaptive</font></b> memory. | Innate: No memory; Adaptive: Immunologic memory.
118. Compare <b><font color="red">MHC Class I vs. Class II</font></b> distribution. | Class I: All nucleated cells; Class II: APCs.
119. Compare <b><font color="red">MHC Class I vs. Class II</font></b> activation. | Class I: CD8+ T cells; Class II: CD4+ T cells.
120. Compare <b><font color="red">Oncogenes vs. Tumor Suppressor Genes</font></b> mechanism. | Oncogenes: Gain of Function; Tumor Suppressors: Loss of Function.
121. Compare <b><font color="red">BRCA1 vs. BRCA2</font></b> chromosome locations. | BRCA1: Chr 17; BRCA2: Chr 13.
122. Contrast <b><font color="red">Amsterdam I vs. Amsterdam II</font></b>. | II includes extracolonic cancers (endometrial, etc).
123. Contrast <b><font color="red">Bethesda vs. Amsterdam II</font></b>. | Bethesda is more sensitive; Amsterdam is more specific.
124. Contrast <b><font color="red">M1 vs. M2 Macrophages</font></b>. | M1: Tumor killing; M2: Tumor growth/evasion.
125. Contrast <b><font color="red">Somatic vs. Germline Mutation</font></b> heritability. | Somatic: Not heritable; Germline: Heritable.
126. Contrast <b><font color="red">Th1 vs. Th2 Cells</font></b> immunity type. | Th1: Cell-mediated (IFN-γ); Th2: Humoral (IL-4).
127. Contrast <b><font color="red">IgG vs. IgM</font></b> placentation. | IgG: Crosses placenta; IgM: Does not cross.
128. Contrast <b><font color="red">HPV E6 vs. E7</font></b> targets. | E6: p53; E7: Rb.
129. Contrast <b><font color="red">Immune Desert vs. Excluded</font></b>. | Desert: Absent cells; Excluded: Stroma-only cells.
130. Contrast <b><font color="red">G-CSF vs. EPO</font></b> targets. | G-CSF: Neutrophils; EPO: Red blood cells.
131. Contrast <b><font color="red">CTLs vs. NK Cells</font></b> recognition. | CTLs require MHC; NK cells kill if MHC is lacking.
132. Compare <b><font color="red">MSI-H vs. dMMR</font></b> relationship. | MSI-H: Phenotype/effect; dMMR: Mechanism/cause.


---
# 3
## Summary
text
### <b><i style="color:red;">I. Principles of Radiation Therapy & Physics</i></b>

* <font color="red">Electromagnetic radiation</font> is a form of energy with no mass or charge that travels at the speed of light.
* The <font color="red">inverse square law</font> states that radiation energy per unit area is inversely proportional to the square of the distance from the source (1/r²).
* The <font color="red">fractional cell kill</font> principle establishes that each delivered radiation dose kills a constant fraction (not a constant number) of tumor cells.
* <font color="red">Therapeutic goal of radiation</font> is to achieve maximum local tumor control while minimizing normal tissue damage and adverse symptoms.
* <font color="red">Radiation resistance</font> is associated with cellular hypoxia, nutritional deficiency, or enhanced cell-mediated repair of DNA damage.
* <font color="red">Photons (X-rays and Gamma rays)</font> are the most common source of radiation used in the treatment of gynecologic malignancies.
* <font color="red">Gamma rays</font> are photons that originate from the atomic nucleus.
* <font color="red">X-rays</font> are photons that originate from extranuclear (atomic orbital) interactions.
* <font color="red">Bremsstrahlung ("braking radiation")</font> is produced when accelerated electrons hit a high atomic number (Z) target, generating photons of various energies.
* <font color="red">Particulate radiation</font> includes alpha particles, protons, neutrons, and electrons, which randomly ionize atoms to produce tissue effects.
* <font color="red">Protons</font> demonstrate a characteristic "Bragg peak," where the peak dose is deposited at the end of the particle's range, sparing initial tissue.

### <b><i style="color:red;">II. Photon Interactions & Radiobiology</i></b>

* <font color="red">Coherent Scattering</font> occurs at low energies (<10 keV) and results in no energy loss or radiobiologic effect.
* <font color="red">Photoelectric Effect</font> (10 to 60 keV) involves total photon absorption and electron ejection; it is responsible for high tissue-bone contrast in imaging.
* <font color="red">Compton Effect</font> (60 keV to 10 MeV) is the predominant interaction in human tissue (90% water) and is the most important interaction at therapeutic energies (4 to 18 MeV).
* <font color="red">Pair Production</font> requires photon energy >1.022 MeV and results in the formation of an electron-positron pair; it is the basis of PET imaging.
* <font color="red">Indirect DNA damage</font> accounts for two-thirds of radiation-induced damage and is caused by the formation of highly reactive hydroxyl radicals (OH) from water.
* <font color="red">Sublethal DNA damage repair</font> occurs more effectively in normal cells than in malignant cells, which often have faulty genomic monitors.
* <font color="red">Intracellular molecular oxygen</font> is essential for "fixing" DNA damage caused by free radicals; tumor hypoxia therefore leads to radiation resistance.
* <font color="red">High-LET (Linear Energy Transfer) radiation</font>, such as neutrons or alpha particles, is densely ionizing and causes cell death independent of tissue oxygenation.
* <font color="red">Amifostine</font> is a radioprotector that scavenges free radicals; it can reduce cisplatin-induced renal toxicity in ovarian cancer.
* <font color="red">Mitotic death</font> is the most common form of radiation-induced cell death, occurring after the cell attempts to divide.

### <b><i style="color:red;">III. Tissue Sensitivity & The Cell Cycle</i></b>

* <font color="red">M phase (Mitosis)</font> is the most radiosensitive phase of the cell cycle because DNA is tightly packaged.
* <font color="red">S phase (DNA Synthesis)</font> is the most radioresistant phase of the cell cycle due to the presence of repair enzymes used during replication.
* <font color="red">Radiosensitivity</font> is highest in rapidly proliferating cells.
* <font color="red">G1 and G2 phases</font> are more radiosensitive than the S phase but less so than the M phase.
* <font color="red">Hemoglobin levels (>10 mg/dL)</font> are associated with improved tumor oxygenation and superior outcomes in cervical cancer radiation therapy.

### <b><i style="color:red;">IV. Radiation Techniques: Teletherapy & Brachytherapy</i></b>

* <font color="red">Teletherapy (External Beam)</font> delivers radiation from a source located at a distance from the patient, typically using linear accelerators.
* <font color="red">Intensity-modulated radiotherapy (IMRT)</font> allows the high-dose radiation region to be conformed precisely to the tumor volume, sparing normal tissues like the small bowel.
* <font color="red">Isodose curves</font> connect points in tissue receiving equivalent doses; higher-energy beams (e.g., 22-MeV) penetrate deeper and spare the skin surface.
* <font color="red">Brachytherapy (Internal)</font> involves placing radioactive sources directly within or near the tumor.
* <font color="red">Intracavitary therapy</font> for cervical cancer typically uses the Fletcher-Suit applicator (tandem and ovoids) to deliver dose to the cervix and paracervical tissues.
* <font color="red">High-dose rate (HDR) brachytherapy</font> is performed on an outpatient basis over 3 to 5 hours, usually repeated 3 to 6 times.
* <font color="red">Low-dose rate (LDR) brachytherapy</font> requires a shielded hospital room, bed rest, and prolonged analgesia as the source remains in place for an extended period.
* <font color="red">Cesium-137 (137Cs)</font> is a commonly used radioisotope in gynecologic brachytherapy with a half-life of 30 years.
* <font color="red">Iridium-192 (192Ir)</font> has a half-life of 73.8 days and is frequently used in modern brachytherapy units.

### <b><i style="color:red;">V. Radiation Complications</i></b>

* <font color="red">Acute radiation effects</font> occur within days to weeks and affect rapidly dividing tissues like skin, intestinal mucosa, and bone marrow.
* <font color="red">Late radiation effects</font> occur months to years later and are caused by vascular damage and connective tissue loss (e.g., fibrosis, fistulas).
* <font color="red">Radiation cystitis</font> presents as dysuria and frequency; it is managed with analgesics like Phenazopyridine.
* <font color="red">Sigmoiditis or enteritis</font> caused by radiation leads to diarrhea, cramping, and malabsorption; management includes a low-roughage diet and antispasmodics.
* <font color="red">Fistulas (vesicovaginal or rectovaginal)</font> typically occur 6 to 24 months post-treatment and often require surgical intervention.
* <font color="red">Radiation recall dermatitis</font> is a skin reaction that occurs when certain chemotherapy agents (e.g., Dactinomycin) are given after previous radiation.

### <b><i style="color:red;">VI. Chemotherapy Principles & Management</i></b>

* <font color="red">Standard of care for advanced ovarian cancer</font> is six cycles of a taxane-platinum combination (e.g., Paclitaxel + Carboplatin).
* <font color="red">Neoadjuvant chemotherapy</font> is given before surgery to reduce tumor size and improve the likelihood of optimal debulking.
* <font color="red">Maintenance therapy</font> is used to prolong stable disease after the initial primary treatment.
* <font color="red">Myelosuppression</font> is the most common serious toxicity of chemotherapy; it is managed with Granulocyte colony-stimulating factor (G-CSF).
* <font color="red">Body Surface Area (BSA)</font> is the standard metric used to calculate most chemotherapy doses.
* <font color="red">RECIST criteria</font> provide a standardized method for measuring tumor response to treatment via imaging.
* <font color="red">Platinum resistance</font> is defined as tumor recurrence or progression within less than 6 months of completing platinum-based therapy.
* <font color="red">Platinum sensitivity</font> is defined as a disease-free interval of more than 6 months after treatment.

### <b><i style="color:red;">VII. Chemotherapeutic Agents: Details & Toxicity</i></b>

| Class | Red Subject(s) | Key Specifics | Toxicity/Side Effects |
| :--- | :--- | :--- | :--- |
| **Platinums** | <font color="red">Cisplatin</font> | Nephrotoxic; requires aggressive hydration. | Ototoxicity, severe N/V, neuropathy. |
| **Platinums** | <font color="red">Carboplatin</font> | Dosed by Calvert formula (AUC); better tolerated. | Dose-limiting thrombocytopenia. |
| **Taxanes** | <font color="red">Paclitaxel</font> | Stabilizes microtubules (M-phase); derived from Yew trees. | Peripheral neuropathy, alopecia, hypersensitivity. |
| **Taxanes** | <font color="red">Docetaxel</font> | Used often if paclitaxel hypersensitivity occurs. | Significant neutropenia. |
| **Antibiotics** | <font color="red">Actinomycin D</font> | Used for GTD; acts on G1 phase. | Myelosuppression, radiation recall. |
| **Antibiotics** | <font color="red">Doxorubicin</font> | Inhibits topoisomerase II; red color. | Irreversible cardiotoxicity (CHF), Hand-foot syndrome. |
| **Antibiotics** | <font color="red">Bleomycin</font> | Produces single-strand breaks via hydroxyl radicals. | **Not** myelosuppressive; causes pulmonary fibrosis. |
| **Topoisomerase** | <font color="red">Topotecan</font> | Inhibits Topoisomerase I. | Severe bone marrow suppression. |
| **Topoisomerase** | <font color="red">Etoposide</font> | Inhibits Topoisomerase II. | Myelosuppression. |
| **Alkylating** | <font color="red">Cyclophosphamide</font> | Forms DNA cross-links. | Hemorrhagic cystitis (prevent with hydration/Mesna). |
| **Antimetabolite** | <font color="red">Methotrexate</font> | Folic acid analog; inhibits dihydrofolate reductase. | Stomatitis, hepatotoxicity; rescue with Folinic acid. |
| **Antimetabolite** | <font color="red">5-Fluorouracil</font> | Inhibits thymidylate synthase. | PPE (Hand-foot syndrome), diarrhea. |
| **Vinca Alkaloid**| <font color="red">Vincristine</font> | Blocks microtubule polymerization. | Severe neurotoxicity and constipation. |
| **Biologic** | <font color="red">Bevacizumab</font> | Monoclonal antibody targeting VEGF (angiogenesis). | Bowel perforation, hypertension, proteinuria. |

### <b><i style="color:red;">VIII. PARP Inhibitors & Hormones</i></b>

* <font color="red">PARP Inhibitors</font> utilize "synthetic lethality" to kill cancer cells that already have deficient DNA repair (e.g., BRCA mutations).
* <font color="red">Olaparib</font> was the first PARP inhibitor approved for BRCA-positive recurrent ovarian cancer.
* <font color="red">Niraparib</font> has shown benefits as consolidation therapy regardless of BRCA status.
* <font color="red">Rucaparib</font> is indicated for platinum-sensitive recurrence after failure of ≥2 lines of chemotherapy.
* <font color="red">Hormonal therapy</font> using Progestins (e.g., Megestrol) is most effective against well-differentiated endometrial carcinomas.

### <b><i style="color:red;">IX. Clinical Trials & Performance Status</i></b>

* <font color="red">Phase I trials</font> primarily evaluate the safety, toxicity, and maximum tolerated dose of a new drug.
* <font color="red">Phase II trials</font> focus on the therapeutic effectiveness of a drug against a specific tumor type.
* <font color="red">Phase III trials</font> compare a new treatment directly against the current standard of care.
* <font color="red">Karnofsky Performance Status</font> measures a patient's functional condition; a score ≤50 indicates a poor candidate for clinical trials.

### <b><i style="color:red;">X. Pregnancy & Radiation (Williams)</i></b>

* <font color="red">Fetal radiation exposure</font> may cause malformations, growth restriction, or carcinogenesis depending on dose and gestational age.
* <font color="red">Week 8 to 15 of gestation</font> is the period of highest risk for radiation-induced intellectual disability (threshold ~0.06 Gy).
* <font color="red">Organogenesis (Weeks 2–8)</font> is the period where radiation exposure is most likely to cause structural congenital malformations (threshold 0.1–0.2 Gy).
* <font color="red">Radiotherapy to the maternal abdomen</font> is contraindicated after 25 weeks of gestation.
* <font color="red">Supradiaphragmatic radiotherapy</font> (e.g., for head and neck cancer) can be used during pregnancy if the fetus is shielded.

### <b><i style="color:red;">XI. Comparison of Similar Entities</i></b>

* <font color="red">Cisplatin vs. Carboplatin</font>: Cisplatin is more nephrotoxic and emetogenic; Carboplatin is more myelosuppressive (thrombocytopenia).
* <font color="red">Teletherapy vs. Brachytherapy</font>: Teletherapy uses an external source at a distance; Brachytherapy uses an internal source placed within or near the tumor.
* <font color="red">Low-LET vs. High-LET</font>: Low-LET (photons) requires oxygen to fix damage; High-LET (alpha/neutrons) kills cells regardless of oxygen presence.
* <font color="red">S-phase vs. M-phase</font>: S-phase is the most radioresistant part of the cell cycle; M-phase is the most radiosensitive.
* <font color="red">Acute vs. Late effects</font>: Acute effects involve rapidly dividing cells (skin/mucosa); Late effects involve slow-renewing tissues (fibrosis/fistula).
* <font color="red">Direct vs. Indirect Action</font>: Direct action is the photon hitting DNA; Indirect action is damage via hydroxyl radicals from water.
* <font color="red">Platinum-sensitive vs. Resistant</font>: Sensitive relapses >6 months after treatment; Resistant relapses <6 months after treatment.
* <font color="red">Paclitaxel vs. Docetaxel</font>: Paclitaxel is derived from Pacific Yew and causes more hypersensitivity; Docetaxel is from English Yew and is more neutropenic.
* <font color="red">Olaparib vs. Niraparib</font>: Olaparib is traditionally for BRCA-mutated patients; Niraparib is often used regardless of BRCA status.
* <font color="red">Phase II vs. Phase III trials</font>: Phase II looks for efficacy in a specific disease; Phase III compares a drug to the gold standard.
* <font color="red">X-rays vs. Gamma rays</font>: X-rays are extranuclear; Gamma rays are nuclear in origin.
* <font color="red">5-FU vs. Doxorubicin Toxicity</font>: 5-FU and liposomal Doxorubicin both cause Hand-Foot Syndrome; However, Doxorubicin is uniquely cardiotoxic.
* <font color="red">Vincristine vs. Paclitaxel</font>: Both cause neuropathy, but Vincristine prevents microtubule polymerization while Paclitaxel prevents depolymerization.
* <font color="red">Ionization vs. Excitation</font>: Ionization removes an electron from an atom; Excitation merely moves it to a higher energy state.
* <font color="red">Amsterdam vs. Bethesda (Context)</font>: While not in this text, remember Bethesda is more sensitive for MSI testing while Amsterdam is specific for Lynch Syndrome.


## QA
text
### <b><i style="color:red;">I. Principles of Radiation Therapy & Physics</i></b>

1. Describe the mass and charge of <b><font color="red">Electromagnetic radiation</font></b>. | No mass or charge. <br>Travels at the speed of light.
2. What is the mathematical relationship in the <b><font color="red">inverse square law</font></b>? | 1/r². <br>Radiation energy per unit area is inversely proportional to the square of the distance.
3. Does <b><font color="red">fractional cell kill</font></b> eliminate a constant number or fraction? | Constant fraction. <br>Each dose kills a constant fraction of tumor cells.
4. What is the primary <b><font color="red">therapeutic goal of radiation</font></b>? | Maximum local tumor control. <br>While minimizing normal tissue damage and adverse symptoms.
5. List three factors associated with <b><font color="red">Radiation resistance</font></b>. (3) | 1) Cellular hypoxia <br>2) Nutritional deficiency <br>3) Enhanced cell-mediated DNA repair
6. What are the most common <b><font color="red">Photons</font></b> used in gynecologic malignancies? | X-rays and Gamma rays.
7. What is the origin of <b><font color="red">Gamma rays</font></b>? | Atomic nucleus.
8. What is the origin of <b><font color="red">X-rays</font></b>? | Extranuclear interactions. <br>Specifically atomic orbital interactions.
9. How is <b><font color="red">Bremsstrahlung ("braking radiation")</font></b> produced? | Accelerated electrons hit high-Z target. <br>Generates photons of various energies.
10. What particles make up <b><font color="red">Particulate radiation</font></b>? (4) | 1) Alpha particles <br>2) Protons <br>3) Neutrons <br>4) Electrons
11. Describe the characteristic <b><font color="red">Bragg peak</font></b> of Protons. | Peak dose at end. <br>Dose is deposited at the end of the particle's range, sparing initial tissue.

### <b><i style="color:red;">II. Photon Interactions & Radiobiology</i></b>

12. Energy level and effect of <b><font color="red">Coherent Scattering</font></b>? | <10 keV. <br>Results in no energy loss or radiobiologic effect.
13. Imaging relevance of the <b><font color="red">Photoelectric Effect</font></b> (10-60 keV)? | High tissue-bone contrast. <br>Involves total photon absorption and electron ejection.
14. Which interaction is predominant in <b><font color="red">human tissue (90% water)</font></b>? | Compton Effect. <br>Occurs at 60 keV to 10 MeV.
15. What is the most important interaction at <b><font color="red">therapeutic energies</font></b> (4-18 MeV)? | Compton Effect.
16. What is the energy requirement for <b><font color="red">Pair Production</font></b>? | >1.022 MeV. <br>Results in an electron-positron pair; basis of PET imaging.
17. What causes two-thirds of <b><font color="red">Indirect DNA damage</font></b>? | Hydroxyl radicals (OH). <br>Formed from water.
18. Comparison of <b><font color="red">Sublethal DNA damage repair</font></b> in normal vs. malignant cells? | More effective in normal cells. <br>Malignant cells often have faulty genomic monitors.
19. Role of <b><font color="red">Intracellular molecular oxygen</font></b> in DNA damage? | "Fixing" DNA damage. <br>Required to fix damage caused by free radicals.
20. Consequence of <b><font color="red">tumor hypoxia</font></b> on radiation? | Radiation resistance.
21. What is the oxygen-dependency of <b><font color="red">High-LET radiation</font></b> cell death? | Independent of oxygenation. <br>Densely ionizing (e.g., neutrons or alpha particles).
22. Mechanism and use of <b><font color="red">Amifostine</font></b>? | Scavenges free radicals. <br>Reduces cisplatin-induced renal toxicity in ovarian cancer.
23. What is the most common form of <b><font color="red">radiation-induced cell death</font></b>? | Mitotic death. <br>Occurs after the cell attempts to divide.

### <b><i style="color:red;">III. Tissue Sensitivity & The Cell Cycle</i></b>

24. Why is the <b><font color="red">M phase (Mitosis)</font></b> the most radiosensitive? | DNA is tightly packaged.
25. Why is the <b><font color="red">S phase (DNA Synthesis)</font></b> the most radioresistant? | Presence of repair enzymes. <br>Used during replication.
26. Relationship between proliferation rate and <b><font color="red">Radiosensitivity</font></b>? | Highest in rapidly proliferating cells.
27. Relative radiosensitivity of <b><font color="red">G1 and G2 phases</font></b>? | Intermediate. <br>More sensitive than S phase, less than M phase.
28. Target <b><font color="red">Hemoglobin levels</font></b> for cervical cancer radiation? | >10 mg/dL. <br>Associated with improved tumor oxygenation and outcomes.

### <b><i style="color:red;">IV. Radiation Techniques: Teletherapy & Brachytherapy</i></b>

29. Define the source location in <b><font color="red">Teletherapy (External Beam)</font></b>. | At a distance. <br>Typically uses linear accelerators.
30. Benefit of <b><font color="red">Intensity-modulated radiotherapy (IMRT)</font></b>? | Precision/Sparing normal tissues. <br>Conforms high-dose region to tumor, sparing small bowel.
31. What do <b><font color="red">Isodose curves</font></b> represent? | Points of equivalent dose.
32. Benefit of <b><font color="red">higher-energy beams</font></b> (e.g., 22-MeV)? | Deeper penetration. <br>Sparing the skin surface.
33. Define <b><font color="red">Brachytherapy (Internal)</font></b> source placement. | Within or near tumor.
34. Common applicator for <b><font color="red">Intracavitary therapy</font></b> in cervical cancer? | Fletcher-Suit applicator. <br>Uses tandem and ovoids.
35. Administration details of <b><font color="red">High-dose rate (HDR) brachytherapy</font></b>? | Outpatient basis. <br>3 to 5 hours, repeated 3 to 6 times.
36. Requirements for <b><font color="red">Low-dose rate (LDR) brachytherapy</font></b>? | Shielded room and bed rest. <br>Source remains in place for an extended period.
37. Half-life of <b><font color="red">Cesium-137 (137Cs)</font></b>? | 30 years.
38. Half-life of <b><font color="red">Iridium-192 (192Ir)</font></b>? | 73.8 days.

### <b><i style="color:red;">V. Radiation Complications</i></b>

39. Timing and targets of <b><font color="red">Acute radiation effects</font></b>? | Days to weeks. <br>Rapidly dividing tissues (skin, mucosa, bone marrow).
40. Cause of <b><font color="red">Late radiation effects</font></b> (months to years)? | Vascular damage. <br>And connective tissue loss (fibrosis, fistulas).
41. Management of <b><font color="red">Radiation cystitis</font></b>? | Phenazopyridine. <br>Presents as dysuria and frequency.
42. Symptoms of <b><font color="red">Sigmoiditis or enteritis</font></b>? | Diarrhea and malabsorption. <br>Includes cramping.
43. Management of <b><font color="red">Radiation-induced bowel symptoms</font></b>? | Low-roughage diet. <br>Also antispasmodics.
44. Timing and management of <b><font color="red">radiation-induced Fistulas</font></b>? | 6 to 24 months. <br>Often require surgical intervention.
45. Define <b><font color="red">Radiation recall dermatitis</font></b>. | Skin reaction to chemo. <br>Occurs after previous radiation (e.g., Dactinomycin).

### <b><i style="color:red;">VI. Chemotherapy Principles & Management</i></b>

46. <b><font color="red">Standard of care for advanced ovarian cancer</font></b>? | Taxane-platinum combination. <br>Example: Paclitaxel + Carboplatin for six cycles.
47. Goal of <b><font color="red">Neoadjuvant chemotherapy</font></b>? | Reduce tumor size. <br>Improve likelihood of optimal debulking.
48. Purpose of <b><font color="red">Maintenance therapy</font></b>? | Prolong stable disease. <br>Given after initial primary treatment.
49. Management of the toxicity <b><font color="red">Myelosuppression</font></b>? | G-CSF. <br>Granulocyte colony-stimulating factor.
50. Standard metric for <b><font color="red">calculating chemotherapy doses</font></b>? | Body Surface Area (BSA).
51. Function of <b><font color="red">RECIST criteria</font></b>? | Standardized tumor measurement. <br>Measuring response via imaging.
52. Definition of <b><font color="red">Platinum resistance</font></b>? | Recurrence within <6 months. <br>Progression after completing platinum therapy.
53. Definition of <b><font color="red">Platinum sensitivity</font></b>? | Interval > 6 months.

### <b><i style="color:red;">VII. Chemotherapeutic Agents: Platinums & Taxanes</i></b>

54. Key toxicity of <b><font color="red">Cisplatin</font></b>? | Nephrotoxic. <br>Requires aggressive hydration.
55. Side effects (3) of <b><font color="red">Cisplatin</font></b>? | 1) Ototoxicity <br>2) Severe N/V <br>3) Neuropathy
56. Dosing method for <b><font color="red">Carboplatin</font></b>? | Calvert formula (AUC).
57. Dose-limiting toxicity of <b><font color="red">Carboplatin</font></b>? | Thrombocytopenia.
58. Mechanism and phase of <b><font color="red">Paclitaxel</font></b>? | Stabilizes microtubules (M-phase). <br>Derived from Yew trees.
59. Side effects (3) of <b><font color="red">Paclitaxel</font></b>? | 1) Peripheral neuropathy <br>2) Alopecia <br>3) Hypersensitivity
60. Indication for <b><font color="red">Docetaxel</font></b>? | Paclitaxel hypersensitivity.
61. Significant toxicity of <b><font color="red">Docetaxel</font></b>? | Neutropenia.

### <b><i style="color:red;">VII. Chemotherapeutic Agents: Antibiotics & Topoisomerase</i></b>

62. Use and phase action of <b><font color="red">Actinomycin D</font></b>? | Used for GTD (G1 phase).
63. Toxicities (2) of <b><font color="red">Actinomycin D</font></b>? | 1) Myelosuppression <br>2) Radiation recall
64. Mechanism and color of <b><font color="red">Doxorubicin</font></b>? | Inhibits topoisomerase II (Red color).
65. Toxicities (2) of <b><font color="red">Doxorubicin</font></b>? | 1) Irreversible cardiotoxicity (CHF) <br>2) Hand-foot syndrome
66. Mechanism of <b><font color="red">Bleomycin</font></b>? | Single-strand breaks. <br>Via hydroxyl radicals.
67. Unique feature and toxicity of <b><font color="red">Bleomycin</font></b>? | NOT myelosuppressive. <br>Causes pulmonary fibrosis.
68. Mechanism and toxicity of <b><font color="red">Topotecan</font></b>? | Inhibits Topoisomerase I. <br>Severe bone marrow suppression.
69. Mechanism and toxicity of <b><font color="red">Etoposide</font></b>? | Inhibits Topoisomerase II. <br>Myelosuppression.

### <b><i style="color:red;">VII. Chemotherapeutic Agents: Alkylating & Antimetabolites</i></b>

70. Mechanism of <b><font color="red">Cyclophosphamide</font></b>? | DNA cross-links.
71. Toxicity and prevention for <b><font color="red">Cyclophosphamide</font></b>? | Hemorrhagic cystitis. <br>Prevent with hydration and Mesna.
72. Mechanism of <b><font color="red">Methotrexate</font></b>? | Inhibits dihydrofolate reductase. <br>Folic acid analog.
73. Toxicities and rescue for <b><font color="red">Methotrexate</font></b>? | Stomatitis/Hepatotoxicity. <br>Rescue with Folinic acid.
74. Mechanism of <b><font color="red">5-Fluorouracil</font></b>? | Inhibits thymidylate synthase.
75. Toxicities (2) of <b><font color="red">5-Fluorouracil</font></b>? | 1) PPE (Hand-foot syndrome) <br>2) Diarrhea

### <b><i style="color:red;">VII. Chemotherapeutic Agents: Vincas & Biologics</i></b>

76. Mechanism of <b><font color="red">Vincristine</font></b>? | Blocks microtubule polymerization.
77. Toxicities (2) of <b><font color="red">Vincristine</font></b>? | 1) Severe neurotoxicity <br>2) Constipation
78. Mechanism of <b><font color="red">Bevacizumab</font></b>? | Monoclonal antibody targeting VEGF. <br>Inhibits angiogenesis.
79. Toxicities (3) of <b><font color="red">Bevacizumab</font></b>? | 1) Bowel perforation <br>2) Hypertension <br>3) Proteinuria

### <b><i style="color:red;">VIII. PARP Inhibitors & Hormones</i></b>

80. Mechanism of <b><font color="red">PARP Inhibitors</font></b>? | Synthetic lethality. <br>Kills cells with deficient DNA repair (BRCA mutations).
81. First PARP inhibitor for <b><font color="red">BRCA-positive recurrent ovarian cancer</font></b>? | Olaparib.
82. Benefit of <b><font color="red">Niraparib</font></b>? | Consolidation regardless of BRCA status.
83. Indication for <b><font color="red">Rucaparib</font></b>? | Platinum-sensitive recurrence. <br>After failure of ≥2 lines of chemotherapy.
84. Best target for <b><font color="red">Hormonal therapy</font></b> (Progestins)? | Well-differentiated endometrial carcinomas.

### <b><i style="color:red;">IX. Clinical Trials & Performance Status</i></b>

85. Purpose of <b><font color="red">Phase I trials</font></b>? | Safety and toxicity. <br>Determines maximum tolerated dose.
86. Purpose of <b><font color="red">Phase II trials</font></b>? | Therapeutic effectiveness. <br>Against a specific tumor type.
87. Purpose of <b><font color="red">Phase III trials</font></b>? | Compare to standard of care.
88. Poor candidate score for <b><font color="red">Karnofsky Performance Status</font></b>? | Score ≤50.

### <b><i style="color:red;">X. Pregnancy & Radiation</i></b>

89. Fetal risks of <b><font color="red">Fetal radiation exposure</font></b>? | Malformations/Growth restriction. <br>Also carcinogenesis.
90. Risks during <b><font color="red">Week 8 to 15 of gestation</font></b>? | Intellectual disability. <br>Threshold ~0.06 Gy.
91. Risks during <b><font color="red">Organogenesis (Weeks 2–8)</font></b>? | Structural malformations. <br>Threshold 0.1–0.2 Gy.
92. When is <b><font color="red">Radiotherapy to the maternal abdomen</font></b> contraindicated? | After 25 weeks of gestation.
93. Condition for using <b><font color="red">Supradiaphragmatic radiotherapy</font></b> in pregnancy? | Fetus must be shielded.

### <b><i style="color:red;">XI. Comparison of Similar Entities (Part 1)</i></b>

94. Compare <b><font color="red">Cisplatin vs. Carboplatin</font></b> nephrotoxicity. | Cisplatin is more nephrotoxic.
95. Compare <b><font color="red">Cisplatin vs. Carboplatin</font></b> myelosuppression. | Carboplatin is more myelosuppressive.
96. Contrast <b><font color="red">Teletherapy vs. Brachytherapy</font></b> source position. | Teletherapy: External source. <br>Brachytherapy: Internal source.
97. Contrast <b><font color="red">Low-LET vs. High-LET</font></b> oxygen requirement. | Low-LET (photons) requires oxygen. <br>High-LET (alpha/neutrons) is oxygen-independent.
98. Contrast <b><font color="red">S-phase vs. M-phase</font></b> radiosensitivity. | S-phase: Most radioresistant. <br>M-phase: Most radiosensitive.
99. Contrast <b><font color="red">Acute vs. Late effects</font></b> tissue types. | Acute: Rapidly dividing (skin/mucosa). <br>Late: Slow-renewing (fibrosis/fistula).
100. Contrast <b><font color="red">Direct vs. Indirect Action</font></b>. | Direct: Photon hits DNA. <br>Indirect: Damage via hydroxyl radicals.

### <b><i style="color:red;">XI. Comparison of Similar Entities (Part 2)</i></b>

101. Define <b><font color="red">Platinum-sensitive vs. Resistant</font></b> based on time. | sensitive: >6 months. <br>Resistant: <6 months.
102. Compare <b><font color="red">Paclitaxel vs. Docetaxel</font></b> origin and toxicity. | Paclitaxel: Pacific Yew/Hypersensitivity. <br>Docetaxel: English Yew/Neutropenic.
103. Compare <b><font color="red">Olaparib vs. Niraparib</font></b> BRCA status use. | Olaparib: BRCA-mutated. <br>Niraparib: Regardless of BRCA status.
104. Contrast <b><font color="red">Phase II vs. Phase III trials</font></b> objective. | Phase II: Efficacy in a disease. <br>Phase III: Comparison to gold standard.
105. Contrast <b><font color="red">X-rays vs. Gamma rays</font></b> origin. | X-rays: Extranuclear. <br>Gamma rays: Nuclear.
106. Compare <b><font color="red">5-FU vs. Doxorubicin Toxicity</font></b> on skin/heart. | Both: Hand-Foot Syndrome. <br>Doxorubicin: Cardiotoxic.
107. Contrast <b><font color="red">Vincristine vs. Paclitaxel</font></b> microtubule effect. | Vincristine: Prevents polymerization. <br>Paclitaxel: Prevents depolymerization.
108. Contrast <b><font color="red">Ionization vs. Excitation</font></b>. | Ionization: Removes electron. <br>Excitation: Moves electron to higher state.
109. <b><font color="red">Amsterdam vs. Bethesda</font></b> context for Lynch Syndrome? | Amsterdam: Specific for Lynch. <br>Bethesda: Sensitive for MSI testing.

### <b><i style="color:red;">XII. Additional Detailed Parameters</i></b>

110. Energy level of the <b><font color="red">Photoelectric Effect</font></b>? | 10 to 60 keV.
111. Energy range of the <b><font color="red">Compton Effect</font></b>? | 60 keV to 10 MeV.
112. Threshold for radiation-induced <b><font color="red">intellectual disability</font></b> (8-15 weeks)? | ~0.06 Gy.
113. Threshold for radiation-induced <b><font color="red">structural malformations</font></b> (2-8 weeks)? | 0.1–0.2 Gy.
114. <b><font color="red">Dactinomycin</font></b> is associated with what radiation complication? | Radiation recall dermatitis.
115. What is the most common serious <b><font color="red">chemotherapy toxicity</font></b>? | Myelosuppression.
116. Primary target of <b><font color="red">Bevacizumab</font></b>? | VEGF (Vascular Endothelial Growth Factor).
117. <b><font color="red">Cyclophosphamide</font></b> class of agent? | Alkylating agent.
118. Which antibiotic is <b><font color="red">red</font></b> in color? | Doxorubicin.
119. <b><font color="red">Topotecan</font></b> inhibits which Topoisomerase? | Topoisomerase I.
120. <b><font color="red">Etoposide</font></b> inhibits which Topoisomerase? | Topoisomerase II.


---
# 4
## Summary
text
### <b><i style="color:red;">I. General Principles of Lower Genital Tract Intraepithelial Neoplasia (LGTIN)</i></b>

* **<font color="red">Lower Genital Tract Intraepithelial Neoplasia (LGTIN)</font>** refers to a group of premalignant epithelial lesions characterized by dysplastic cellular changes confined to the epithelium of the cervix, vagina, and vulva without invasion of the basement membrane.
* In the pathology of LGTIN, <b><font color="red">Dysplasia</font></b> is initially identified microscopically through nuclear and cytoplasmic changes before becoming grossly visible.
* The <b><font color="red">Lower Genital Tract</font></b> specifically includes the vulva (external), vagina, and cervix.

### <b><i style="color:red;">II. Cervical Anatomy & The Transformation Zone (TZ)</i></b>

| Feature | **<font color="red">Columnar Epithelium</font>** | **<font color="red">Squamous Epithelium</font>** |
| :--- | :--- | :--- |
| **Location** | Lines the endocervical canal. | Covers the exocervix. |
| **Meeting Point** | Forms the <b><font color="red">Squamocolumnar Junction (SCJ)</font></b>. | Forms the <b><font color="red">Squamocolumnar Junction (SCJ)</font></b>. |
| **Physiology** | Secrets mucus; undergoes metaplasia. | Protective outer layer. |

* The **<font color="red">Squamocolumnar Junction (SCJ)</font>** is a dynamic point that rarely remains at the external os, changing position in response to puberty, pregnancy, menopause, and hormones.
* In **<font color="red">Neonates</font>**, the SCJ is located at the exocervix.
* During **<font color="red">Menarche</font>**, estrogen causes glycogen accumulation, which lactobacilli convert to acid, stimulating normal physiological **<font color="red">Squamous metaplasia</font>** in the squamocolumnar reserve cells.
* The ideal area for specimen collection for **<font color="red">HPV or disease detection</font>** is the active squamocolumnar junction.

| Life Stage | Estrogen Level | **<font color="red">SCJ Location</font>** | **<font color="red">Transformation Zone (TZ)</font>** |
| :--- | :--- | :--- | :--- |
| **Premenarchal** | Low | Inside the endocervical canal | Absent or minimal |
| **Reproductive** | Normal | Ectocervix | Active and visible |
| **Pregnancy** | Very High | Widely everted on ectocervix | Large and exposed |
| **Postmenopausal** | Low | Regressed inside the canal | Regressed/difficult to see |

* The **<font color="red">Transformation Zone</font>** is highly vulnerable to HPV because it is an area of active squamous metaplasia with high cell turnover where immature basal cells are exposed.

### <b><i style="color:red;">III. Classification of Cervical Intraepithelial Neoplasia (CIN)</i></b>

| WHO Grade | Epithelial Thickness Involved | Former Dysplasia Term |
| :--- | :--- | :--- |
| **<font color="red">CIN 1</font>** | Atypical cells in < 1/3 of the thickness. | Mild Dysplasia |
| **<font color="red">CIN 2</font>** | Involvement of 1/3 to 2/3 of the thickness. | Moderate Dysplasia |
| **<font color="red">CIN 3</font>** | Involvement of full thickness of epithelium. | Severe Dysplasia / Carcinoma in Situ (CIS) |

* **<font color="red">Atypical cells</font>** in CIN are microscopically characterized by:
    1) Increased nuclear-cytoplasmic ratio
    2) Increased nuclear size
    3) Loss of polarity
    4) Increased mitotic figures
    5) Hyperchromasia
* In the **<font color="red">2021 Bethesda System</font>**, Squamous Cell Abnormalities are divided into:
    * **<font color="red">ASC-US</font>**: Atypical squamous cells of undetermined significance.
    * **<font color="red">ASC-H</font>**: Atypical squamous cells, cannot exclude HSIL.
    * **<font color="red">LSIL</font>**: Low-grade squamous intraepithelial lesion (includes CIN 1 and HPV effects).
    * **<font color="red">HSIL</font>**: High-grade squamous intraepithelial lesion (includes CIN 2, CIN 3, and CIS).
* In the **<font color="red">Bethesda System</font>**, Glandular Cell Abnormalities include:
    * **<font color="red">AGC</font>**: Atypical glandular cells.
    * **<font color="red">AIS</font>**: Endocervical adenocarcinoma in situ.
* **<font color="red">LSIL</font>** is characterized by high viral replication with mild alteration in host cell growth, while **<font color="red">HSIL</font>** involves low viral replication with high cellular dysregulation.

### <b><i style="color:red;">IV. Human Papillomavirus (HPV) Pathogenesis</i></b>

* **<font color="red">Genital HPV</font>** is the most common sexually transmitted infection (STI); nearly all sexually active individuals will acquire at least one type in their lifetime.
* **<font color="red">HPV 16</font>** is the most common high-risk oncogenic type; other high-risk types include **<font color="red">HPV 18, 31, 33, 45, 52, and 58</font>**.
* **<font color="red">HPV 6 and 11</font>** are low-risk types primarily associated with genital warts (condyloma acuminata).
* For malignancy to occur, the single most important step is **<font color="red">Persistent infection</font>** with high-risk HPV and failure of host immune clearance.
* During **<font color="red">Oncogenic infection</font>**, viral DNA integrates into the host genome, which disrupts the **<font color="red">E2 gene</font>**; because E2 normally suppresses E6 and E7, its loss leads to uncontrolled oncoprotein expression.

| Oncoprotein | Primary Target | Mechanism/Effect |
| :--- | :--- | :--- |
| **<font color="red">E6 Oncoprotein</font>** | **p53** tumor suppressor | Degrades p53; leads to loss of DNA damage checkpoint and inhibition of apoptosis. |
| **<font color="red">E7 Oncoprotein</font>** | **Retinoblastoma (Rb)** protein | Inactivates Rb; causes uncontrolled progression from G1 to S phase and continuous cell cycling. |

* **<font color="red">Koilocytosis</font>**, characterized by nuclear enlargement and perinuclear clearing, is a hallmark cellular change of early/low-grade HPV lesions.

### <b><i style="color:red;">V. Screening and Risk Factors</i></b>

* Factors increasing **<font color="red">Risk for HPV/CIN</font>** include:
    1) Young age at first intercourse
    2) Multiple sex partners
    3) Male partner with multiple partners
    4) Smoking (local immunosuppression)
    5) Nutritional deficiencies
* **<font color="red">ACOG/USPSTF Screening Guidelines</font>** for average-risk women:
    * **Ages 21–24**: Cytology (Pap) alone every 3 years.
    * **Ages 25–29**: Preferred Primary HR-HPV testing every 5 years (ACS) or Pap alone every 3 years.
    * **Ages 30–65**: Preferred Primary HR-HPV testing every 5 years OR co-testing (Pap + HPV) every 5 years.
* Screening may be **<font color="red">Discontinued at age >65</font>** if there is "adequate prior screening" (2 negative HPV/Co-tests or 3 negative Pap tests in 10 years) and no history of CIN 2+ in the last 25 years.
* **<font color="red">DES (Diethylstilbestrol) Exposure</font>** in utero requires annual cytology due to increased risk of clear cell adenocarcinoma.
* **<font color="red">Liquid-based cytology (LBC)</font>** (e.g., ThinPrep) was developed to reduce contamination (blood/mucus) and provide more representative samples compared to conventional Pap smears.

### <b><i style="color:red;">VI. Diagnostic Evaluation</i></b>

* **<font color="red">Colposcopy</font>** is a low-power binocular microscope exam of the cervix used after abnormal cytology; it is considered **"Satisfactory"** only if the entire transformation zone is visualized.
* **<font color="red">Acetowhite Epithelium</font>** appears when 3%–5% acetic acid is applied, coagulating nuclear proteins in dysplastic cells to reflect light.
* **<font color="red">Leukoplakia</font>** is a white plaque visible on the cervix *before* the application of acetic acid, caused by a keratin layer.
* **<font color="red">Punctation</font>** refers to dilated capillaries appearing as dots on the surface; when found in acetowhite areas, they often indicate CIN.
* **<font color="red">Schiller’s Test (VILI)</font>** uses Lugol's iodine; normal cells (rich in glycogen) stain mahogany brown, while dysplastic cells remain unstained (yellow/pale).
* **<font color="red">Endocervical Curettage (ECC)</font>** is recommended if the colposcopic exam is unsatisfactory or if there is abnormal cytology without a visible lesion.

### <b><i style="color:red;">VII. Management of Cervical Lesions</i></b>

* **<font color="red">Cryotherapy</font>** destroys the surface epithelium by crystallizing intracellular water using Nitrous oxide (-89°C) or CO2 (-65°C); it requires a **3–5–3 double freeze–thaw cycle**.
* **<font color="red">Cryotherapy Criteria</font>**: Acceptable for persistent CIN 1 (24 months) or CIN 2 if the lesion is small, ectocervical, and the ECC is negative.
* **<font color="red">Laser Ablation</font>** uses a CO2 laser to vaporize tissue to a depth of ~5 mm; it produces no prolonged discharge but provides no tissue specimen.
* **<font color="red">Loop Electrosurgical Excision Procedure (LEEP/LLETZ)</font>** is the most common US treatment for CIN 2/3; it uses a wire loop to excise the TZ and provide a tissue specimen for pathology.
* **<font color="red">Cold Knife Conization (CKC)</font>** is an excisional procedure done with a scalpel in an OR; it is preferred for **Glandular abnormalities (AIS)** or suspected invasive cancer because it avoids thermal artifact on margins.
* **<font color="red">Hysterectomy</font>** is a treatment of last resort for CIN, indicated for microinvasion, recurrent high-grade CIN, or if other gynecologic issues (e.g., fibroids/prolapse) coexist.

### <b><i style="color:red;">VIII. Vaginal and Vulvar Intraepithelial Neoplasia (VaIN & VIN)</i></b>

* **<font color="red">Vaginal Intraepithelial Neoplasia (VaIN)</font>** is most commonly found in the upper third of the vagina and is frequently associated with a history of CIN or cervical cancer.
* **<font color="red">VaIN Management</font>**: VaIN 1 is monitored via surveillance; VaIN 2 and 3 require treatment (excision or ablation) due to a 2%–5% progression risk to invasive cancer.
* **<font color="red">Usual-type VIN (uVIN/HSIL)</font>** is the most common form of vulvar neoplasia, caused by high-risk HPV (HPV 16), seen in younger women, and often multifocal.
* **<font color="red">Differentiated-type VIN (dVIN)</font>** is NOT HPV-related; it is associated with chronic inflammation (lichen sclerosus), occurs in older women, and has a higher risk of progression to squamous cell carcinoma.
* Symptoms of **<font color="red">Vulvar Intraepithelial Neoplasia (VIN)</font>** include pruritus (itching), burning, and visible color changes (white, red, or pigmented); many remain asymptomatic.
* **<font color="red">Imiquimod cream</font>** is a topical immune response modifier used for VIN and genital warts; **<font color="red">Trichloroacetic acid</font>** is used for pregnant women with external warts.

### <b><i style="color:red;">IX. Prophylaxis: HPV Vaccines</i></b>

| Vaccine Type | **<font color="red">Bivalent (Cervarix)</font>** | **<font color="red">Quadrivalent (Gardasil)</font>** | **<font color="red">9-valent (Gardasil 9)</font>** |
| :--- | :--- | :--- | :--- |
| **HPV Types** | 16, 18 | 6, 11, 16, 18 | 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| **Primary Goal** | Cervical Cancer prevention | Cancer + Genital Warts | Broadest cancer + wart protection |
| **Schedule** | 0, 1, 6 months | 0, 2, 6 months | 2 or 3 dose schedule |

* **<font color="red">HPV Vaccines</font>** work by stimulating neutralizing antibodies; they are prophylactic and cannot treat existing HPV disease or cancer.
* **<font color="red">Total abstinence</font>** from all genital contact is the most effective prevention method for HPV.

### <b><i style="color:red;">X. Comparison of Similar Entities</i></b>

* **<font color="red">LSIL vs. HSIL Natural History</font>**: 60% of LSIL regresses and only 10% progresses to carcinoma, whereas 30% of HSIL regresses and 10% progresses to carcinoma.
* **<font color="red">CIN 1 vs. CIN 3 Involvement</font>**: CIN 1 involves the lower 1/3 of the epithelium thickness, while CIN 3 involves the full thickness of the epithelium.
* **<font color="red">uVIN vs. dVIN Etiology</font>**: uVIN is caused by oncogenic HPV (mainly type 16), whereas dVIN is associated with chronic inflammatory conditions like Lichen Sclerosus and is HPV-negative.
* **<font color="red">Ablative vs. Excisional Therapy</font>**: Ablative therapies (Cryo/Laser) destroy tissue and provide no specimen, while excisional therapies (LEEP/CKC) provide a tissue specimen to rule out invasive cancer.
* **<font color="red">LEEP vs. Cold Knife Conization (CKC)</font>**: LEEP is done in-office with thermal energy (risk of thermal artifact), whereas CKC is done in the OR with a scalpel (preferred for AIS and margin assessment).
* **<font color="red">E6 vs. E7 Oncoproteins</font>**: E6 binds and degrades p53 (stopping apoptosis), while E7 inactivates Rb (allowing continuous cell cycling).
* **<font color="red">Acetowhite vs. Leukoplakia</font>**: Acetowhite epithelium only appears *after* acetic acid application; Leukoplakia is white *before* any solution is applied.
* **<font color="red">Surgical vs. Medical VIN Treatment</font>**: Surgical excision/laser is used for localized or suspected invasive VIN, while Imiquimod is a medical topical therapy used for diffuse disease.
* **<font color="red">Pregnancy vs. Non-pregnancy CIN Management</font>**: In pregnancy, CIN is usually managed expectantly and ECC is contraindicated; postpartum, many low-grade lesions regress.
* **<font color="red">Bivalent vs. Quadrivalent Vaccine</font>**: Bivalent (16, 18) only covers cancer-causing types, whereas Quadrivalent (6, 11, 16, 18) covers both cancer and genital warts.
* **<font color="red">Cytology Sensitivity vs. HPV Testing</font>**: Standard Pap smear has lower sensitivity (~51%) compared to HR-HPV testing, leading to the preference for HPV testing in modern screening.


## QA
text
### <b><i style="color:red;">I. General Principles of LGTIN</i></b>

1. Describe <b><font color="red">Lower Genital Tract Intraepithelial Neoplasia (LGTIN)</font></b>. | Premalignant lesions with dysplastic changes.
2. Where are cellular changes confined in <b><font color="red">LGTIN</font></b>? | Epithelium (no basement membrane invasion).
3. Anatomy: Components of the <b><font color="red">Lower Genital Tract</font></b>? (3) | Vulva, Vagina, and Cervix.
4. How is <b><font color="red">Dysplasia</font></b> initially identified in the pathology of LGTIN? | Microscopically (nuclear and cytoplasmic changes).
5. At what point does <b><font color="red">Dysplasia</font></b> in LGTIN become grossly visible? | After microscopic nuclear/cytoplasmic changes occur.

### <b><i style="color:red;">II. Cervical Anatomy & The Transformation Zone (TZ)</i></b>

6. Location: <b><font color="red">Columnar Epithelium</font></b>? | Lines the endocervical canal.
7. Location: <b><font color="red">Squamous Epithelium</font></b>? | Covers the exocervix.
8. What is the meeting point of Columnar and Squamous epithelium? | <b><font color="red">Squamocolumnar Junction (SCJ)</font></b>.
9. Physiology: <b><font color="red">Columnar Epithelium</font></b>? | Secretes mucus; undergoes metaplasia.
10. Physiology: <b><font color="red">Squamous Epithelium</font></b>? | Protective outer layer.
11. Describe the nature of the <b><font color="red">Squamocolumnar Junction (SCJ)</font></b> position. | Dynamic point (rarely at external os).
12. Factors changing the <b><font color="red">Squamocolumnar Junction (SCJ)</font></b> position? (4) | Puberty, pregnancy, menopause, and hormones.
13. Where is the <b><font color="red">SCJ</font></b> located in neonates? | Exocervix.
14. Effect of estrogen on glycogen in <b><font color="red">Menarche</font></b>? | Causes glycogen accumulation.
15. Role of lactobacilli in <b><font color="red">Squamous metaplasia</font></b> during menarche? | Converts glycogen to acid.
16. Target of <b><font color="red">Squamous metaplasia</font></b> stimulus? | Squamocolumnar reserve cells.
17. Ideal area for <b><font color="red">HPV or disease detection</font></b> collection? | Active squamocolumnar junction.
18. Estrogen level: <b><font color="red">Premenarchal</font></b> stage? | Low.
19. <b><font color="red">SCJ Location</font></b>: Premenarchal stage? | Inside the endocervical canal.
20. <b><font color="red">Transformation Zone (TZ)</font></b>: Premenarchal stage? | Absent or minimal.
21. Estrogen level: <b><font color="red">Reproductive</font></b> stage? | Normal.
22. <b><font color="red">SCJ Location</font></b>: Reproductive stage? | Ectocervix.
23. <b><font color="red">Transformation Zone (TZ)</font></b>: Reproductive stage? | Active and visible.
24. Estrogen level: <b><font color="red">Pregnancy</font></b>? | Very High.
25. <b><font color="red">SCJ Location</font></b>: Pregnancy? | Widely everted on ectocervix.
26. <b><font color="red">Transformation Zone (TZ)</font></b>: Pregnancy? | Large and exposed.
27. Estrogen level: <b><font color="red">Postmenopausal</font></b> stage? | Low.
28. <b><font color="red">SCJ Location</font></b>: Postmenopausal stage? | Regressed inside the canal.
29. <b><font color="red">Transformation Zone (TZ)</font></b>: Postmenopausal stage? | Regressed/difficult to see.
30. Why is the <b><font color="red">Transformation Zone</font></b> highly vulnerable to HPV? | Active metaplasia with high turnover.
31. Cells exposed in the <b><font color="red">Transformation Zone</font></b> during metaplasia? | Immature basal cells.

### <b><i style="color:red;">III. Classification of Cervical Intraepithelial Neoplasia (CIN)</i></b>

32. Epithelial thickness involved: <b><font color="red">CIN 1</font></b>? | Atypical cells in < 1/3 thickness.
33. Former dysplasia term: <b><font color="red">CIN 1</font></b>? | Mild Dysplasia.
34. Epithelial thickness involved: <b><font color="red">CIN 2</font></b>? | 1/3 to 2/3 thickness.
35. Former dysplasia term: <b><font color="red">CIN 2</font></b>? | Moderate Dysplasia.
36. Epithelial thickness involved: <b><font color="red">CIN 3</font></b>? | Full thickness of epithelium.
37. Former terms (2) for <b><font color="red">CIN 3</font></b>? | Severe Dysplasia / Carcinoma in Situ.
38. Microscopic characteristics: <b><font color="red">Atypical cells</font></b> in CIN? (5) | 1) High N:C ratio<br>2) Large nuclei<br>3) Loss of polarity<br>4) Mitotic figures<br>5) Hyperchromasia.
39. Full name of <b><font color="red">ASC-US</font></b>? | Atypical squamous cells of undetermined significance.
40. Full name of <b><font color="red">ASC-H</font></b>? | Atypical squamous cells, cannot exclude HSIL.
41. Components included in <b><font color="red">LSIL</font></b>? (2) | CIN 1 and HPV effects.
42. Components included in <b><font color="red">HSIL</font></b>? (3) | CIN 2, CIN 3, and CIS.
43. Full name of <b><font color="red">AGC</font></b>? | Atypical glandular cells.
44. Full name of <b><font color="red">AIS</font></b>? | Endocervical adenocarcinoma in situ.
45. Pathogenesis of <b><font color="red">LSIL</font></b>? | High viral replication; mild host cell alteration.
46. Pathogenesis of <b><font color="red">HSIL</font></b>? | Low viral replication; high cellular dysregulation.

### <b><i style="color:red;">IV. Human Papillomavirus (HPV) Pathogenesis</i></b>

47. Significance of <b><font color="red">Genital HPV</font></b> among STIs? | Most common sexually transmitted infection.
48. Most common <b><font color="red">high-risk oncogenic HPV</font></b> type? | HPV 16.
49. List of <b><font color="red">high-risk HPV</font></b> types (6)? | 18, 31, 33, 45, 52, and 58.
50. Common <b><font color="red">low-risk HPV</font></b> types? (2) | HPV 6 and 11.
51. Condition associated with <b><font color="red">HPV 6 and 11</font></b>? | Genital warts (condyloma acuminata).
52. Essential step for malignancy in <b><font color="red">HPV infection</font></b>? | Persistent infection.
53. Host factor preventing HPV malignancy? | Host immune clearance.
54. Gene disrupted by HPV DNA integration into host genome? | <b><font color="red">E2 gene</font></b>.
55. Result of <b><font color="red">E2 gene</font></b> loss in HPV? | Uncontrolled oncoprotein expression (E6/E7).
56. Target of <b><font color="red">E6 Oncoprotein</font></b>? | <b>p53</b> tumor suppressor.
57. Mechanism of <b><font color="red">E6 Oncoprotein</font></b>? | Degrades p53; inhibits apoptosis.
58. Target of <b><font color="red">E7 Oncoprotein</font></b>? | <b>Retinoblastoma (Rb)</b> protein.
59. Mechanism of <b><font color="red">E7 Oncoprotein</font></b>? | Inactivates Rb; uncontrolled G1 to S phase.
60. Cell cycling effect of <b><font color="red">E7 Oncoprotein</font></b>? | Continuous cell cycling.
61. Hallmark cellular changes of <b><font color="red">Koilocytosis</font></b>? (2) | Nuclear enlargement and perinuclear clearing.
62. <b><font color="red">Koilocytosis</font></b> is typical for which grade of HPV lesions? | Early or low-grade.

### <b><i style="color:red;">V. Screening and Risk Factors</i></b>

63. Risk factors (5) for <b><font color="red">HPV/CIN</font></b>? | 1) Young age coitus<br>2) Multiple partners<br>3) Male partner habits<br>4) Smoking<br>5) Nutritional deficiencies.
64. Screening ages 21–24: <b><font color="red">ACOG Guidelines</font></b>? | Cytology (Pap) alone every 3 years.
65. Preferred screening ages 25–29: <b><font color="red">ACS/ACOG</font></b>? | Primary HR-HPV testing every 5 years.
66. Option for ages 25–29: <b><font color="red">ACOG Screening</font></b>? | Pap alone every 3 years.
67. Preferred screening ages 30–65? (2 options) | Primary HR-HPV every 5 years OR co-testing every 5 years.
68. When can <b><font color="red">Screening</font></b> be discontinued (age)? | >65 years.
69. Criteria for <b><font color="red">Adequate prior screening</font></b> at age 65? (2 options) | 2 negative HPV/Co-tests OR 3 negative Paps (in 10 years).
70. History clause to discontinue <b><font color="red">Screening</font></b> at age 65? | No CIN 2+ in last 25 years.
71. Screening requirement for <b><font color="red">DES Exposure</font></b>? | Annual cytology.
72. Cancer risk associated with <b><font color="red">DES Exposure</font></b>? | Clear cell adenocarcinoma.
73. Goal of <b><font color="red">Liquid-based cytology (LBC)</font></b> development? | Reduce contamination (blood/mucus).

### <b><i style="color:red;">VI. Diagnostic Evaluation</i></b>

74. Describe <b><font color="red">Colposcopy</font></b>. | Low-power binocular microscope exam of cervix.
75. Requirement for a <b><font color="red">Satisfactory Colposcopy</font></b>? | Entire transformation zone visualized.
76. What causes <b><font color="red">Acetowhite Epithelium</font></b>? | 3%–5% acetic acid application.
77. Mechanism of <b><font color="red">Acetowhite Epithelium</font></b>? | Coagulates nuclear proteins to reflect light.
78. What is <b><font color="red">Leukoplakia</font></b>? | White plaque visible *before* acetic acid.
79. Cause of <b><font color="red">Leukoplakia</font></b>? | Keratin layer.
80. Describe <b><font color="red">Punctation</font></b> on the cervix. | Dilated capillaries appearing as dots.
81. Clinical significance of <b><font color="red">Punctation</font></b> in acetowhite areas? | Often indicates CIN.
82. Solution used in <b><font color="red">Schiller’s Test (VILI)</font></b>? | Lugol’s iodine.
83. Appearance of normal cells in <b><font color="red">Schiller’s Test</font></b>? | Mahogany brown (rich in glycogen).
84. Appearance of dysplastic cells in <b><font color="red">Schiller’s Test</font></b>? | Yellow/pale (unstained).
85. Recommendation for <b><font color="red">Endocervical Curettage (ECC)</font></b>? | Unsatisfactory colposcopy or abnormal cytology without lesion.

### <b><i style="color:red;">VII. Management of Cervical Lesions</i></b>

86. Define <b><font color="red">Cryotherapy</font></b> mechanism. | Crystallizing intracellular water to destroy epithelium.
87. Agents used in <b><font color="red">Cryotherapy</font></b>? (2) | Nitrous oxide or CO2.
88. Required cycle for <b><font color="red">Cryotherapy</font></b>? | 3–5–3 double freeze–thaw cycle.
89. When is <b><font color="red">Cryotherapy</font></b> acceptable? (3) | Persistent CIN 1 (24 mo), small CIN 2, negative ECC.
90. Describe <b><font color="red">Laser Ablation</font></b> depth? | Vaporizes tissue to ~5 mm.
91. Disadvantage of <b><font color="red">Laser Ablation</font></b>? | Provides no tissue specimen.
92. Most common treatment for <b><font color="red">CIN 2/3</font></b> in the US? | Loop Electrosurgical Excision Procedure (LEEP).
93. Benefit of <b><font color="red">LEEP/LLETZ</font></b>? | Provides tissue specimen for pathology.
94. Preferred procedure for <b><font color="red">Glandular abnormalities (AIS)</font></b>? | Cold Knife Conization (CKC).
95. Why is <b><font color="red">CKC</font></b> used for suspected invasive cancer? | Avoids thermal artifact on margins.
96. Indication for <b><font color="red">Hysterectomy</font></b> in CIN? (3) | Microinvasion, recurrent high-grade CIN, or coexisting gyn issues.

### <b><i style="color:red;">VIII. Vaginal and Vulvar Intraepithelial Neoplasia (VaIN & VIN)</i></b>

97. Common location: <b><font color="red">Vaginal Intraepithelial Neoplasia (VaIN)</font></b>? | Upper third of the vagina.
98. Common association for <b><font color="red">VaIN</font></b>? | Prior history of CIN or cervical cancer.
99. Management: <b><font color="red">VaIN 1</font></b>? | Surveillance.
100. Management: <b><font color="red">VaIN 2 and 3</font></b>? | Excision or ablation.
101. Risk of progression for untreated <b><font color="red">VaIN 2/3</font></b>? | 2%–5% to invasive cancer.
102. Most common form of vulvar neoplasia? | <b><font color="red">Usual-type VIN (uVIN/HSIL)</font></b>.
103. Etiology: <b><font color="red">Usual-type VIN</font></b>? | High-risk HPV (mainly HPV 16).
104. Typical patient profile: <b><font color="red">uVIN</font></b>? | Younger women.
105. Etiology: <b><font color="red">Differentiated-type VIN (dVIN)</font></b>? | Chronic inflammation (Lichen Sclerosus); HPV-negative.
106. Progression risk: <b><font color="red">dVIN vs uVIN</font></b>? | dVIN has higher progression risk to SCC.
107. Symptoms (3): <b><font color="red">Vulvar Intraepithelial Neoplasia (VIN)</font></b>? | Pruritus, burning, visible color changes.
108. Medical use: <b><font color="red">Imiquimod cream</font></b>? | Topical immune response modifier for VIN/warts.
109. Treatment for external warts in <b><font color="red">pregnant women</font></b>? | Trichloroacetic acid.

### <b><i style="color:red;">IX. Prophylaxis: HPV Vaccines</i></b>

110. HPV types covered: <b><font color="red">Bivalent (Cervarix)</font></b>? | 16 and 18.
111. HPV types covered: <b><font color="red">Quadrivalent (Gardasil)</font></b>? | 6, 11, 16, and 18.
112. HPV types covered: <b><font color="red">9-valent (Gardasil 9)</font></b>? | 6, 11, 16, 18, 31, 33, 45, 52, 58.
113. Goal: <b><font color="red">Bivalent Vaccine</font></b>? | Cervical cancer prevention.
114. Goal: <b><font color="red">Quadrivalent Vaccine</font></b>? | Cancer and Genital Warts prevention.
115. Benefit: <b><font color="red">9-valent Vaccine</font></b>? | Broadest cancer and wart protection.
116. Mechanism: <b><font color="red">HPV Vaccines</font></b>? | Stimulating neutralizing antibodies.
117. Limitation: <b><font color="red">HPV Vaccines</font></b>? | Prophylactic only (cannot treat existing disease).
118. Most effective <b><font color="red">HPV prevention</font></b> method? | Total abstinence from genital contact.

### <b><i style="color:red;">X. Comparison of Similar Entities</i></b>

119. Natural history: <b><font color="red">LSIL regression</font></b> rate? | 60%.
120. Natural history: <b><font color="red">HSIL regression</font></b> rate? | 30%.
121. Natural history: Carcinoma progression in <b><font color="red">LSIL vs HSIL</font></b>? | 10% for both.
122. Compare epithelial thickness: <b><font color="red">CIN 1 vs. CIN 3</font></b>? | CIN 1: lower 1/3; CIN 3: full thickness.
123. Etiology: <b><font color="red">uVIN vs dVIN</font></b>? | uVIN: Oncogenic HPV; dVIN: HPV-negative/Lichen Sclerosus.
124. Therapy contrast: <b><font color="red">Ablative vs Excisional</font></b>? | Ablative: no specimen; Excisional: provides specimen.
125. Feature: <b><font color="red">LEEP artifact risk</font></b>? | Thermal artifact.
126. Procedure choice: <b><font color="red">AIS or margin assessment</font></b>? | Cold Knife Conization (CKC).
127. Function: <b><font color="red">E6 vs E7</font></b>? | E6 degrades p53 (stops apoptosis); E7 inactivates Rb (allows cell cycle).
128. Identification timing: <b><font color="red">Acetowhite vs Leukoplakia</font></b>? | Acetowhite: *after* acid; Leukoplakia: *before* acid.
129. VIN treatment: <b><font color="red">Surgical vs Medical</font></b> usage? | Surgical: localized/invasive; Medical (Imiquimod): diffuse disease.
130. Management difference: <b><font color="red">Pregnancy vs Non-pregnancy CIN</font></b>? | Pregnancy: expectant management; ECC is contraindicated.
131. Vaccine coverage: <b><font color="red">Bivalent vs Quadrivalent</font></b>? | Bivalent: cancer types; Quadrivalent: cancer + warts.
132. Sensitivity: <b><font color="red">Cytology vs HR-HPV Testing</font></b>? | Cytology lower (~51%) than HR-HPV.


---
# 5
## Summary


## QA


---
